Podcasts about Keynote

In public speaking, a talk that establishes a main underlying theme

  • 6,280PODCASTS
  • 15,689EPISODES
  • 41mAVG DURATION
  • 2DAILY NEW EPISODES
  • Jul 18, 2025LATEST
Keynote

POPULARITY

20172018201920202021202220232024

Categories




Best podcasts about Keynote

Show all podcasts related to keynote

Latest podcast episodes about Keynote

programmier.bar – der Podcast für App- und Webentwicklung
Spezialfolge 186: WeAreDevelopers World Congress aus Berlin

programmier.bar – der Podcast für App- und Webentwicklung

Play Episode Listen Later Jul 18, 2025 33:56


Das Team der programmier.bar meldet sich mit frischen Eindrücken von der WeAreDevelopers Konferenz in Berlin.Dennis Becker, Garrelt Mock und David Koschitzki berichten von der größten Entwicklerkonferenz Europas und erzählen, was sie alles über generative AI, Agenten, Developer Tools und viele andere Technologien erfahren haben.Mit dabei sind Eindrücke von der Keynote von GitHub-CEO Thomas Dohmke, inklusive traditioneller Live-Coding-Pannen wie schon vor drei Jahren. Außerdem gab's inspirierende Talks von alten Hasen aus der Gaming-Branche und jede Menge Konferenz-Vibes, getoppt von einer legendären Party und kleinen Frustrationen wie dem selbst bezahlten Mittagessen.Vielleicht helfen euch unsere Eindrücke bei der Entscheidung, ob sich ein Besuch der nächsten WeAreDevelopers für euch lohnt!Schreibt uns! Schickt uns eure Themenwünsche und euer Feedback: podcast@programmier.barFolgt uns! Bleibt auf dem Laufenden über zukünftige Folgen und virtuelle Meetups und beteiligt euch an Community-Diskussionen. BlueskyInstagramLinkedInMeetupYouTube

Teaching in Higher Ed
Lessons in Love and Learning from Mr. Rogers' Legacy

Teaching in Higher Ed

Play Episode Listen Later Jul 17, 2025 44:29


Jennifer Baumgartner shares some lessons in love and learning from Mr. Rogers' legacy on episode 579 of the Teaching in Higher Ed podcast. Quotes from the episode Mr. Rodgers was a very comforting influence as a young child. -Jennifer Baumgartner Moving slowly or taking your time is a very key theme of Mr. Rogers neighborhood, and also Fred Rogers' life and the way he lived it. -Jennifer Baumgartner He didn't shy away from talking about difficult subjects. -Jennifer Baumgartner Anything that is mentionable is manageable. -Jennifer Baumgartner Resources Fred Rogers Institute Fred Rogers Institute at Saint Vincent College The Neighborhood of Make-Believe You don't have to wait for the clock to strike to start teaching, by Peter Newbury Go Somewhere: Reimagining Technology in Education for a Better Tomorrow, Bonni Stachowiak's Keynote at LSU's Faculty Colloquium Speaking Freddish: How to Sound Like Mister Rogers, by Alexei Novak “Did You Know?” Song by Mister Rogers 10 to 25: The Science of Motivating Young People, by David Yeager Cartoon about writing Teaching C-I Substack Fred Rogers Archive OuiSi Original: Games of Visual Connection Thomas Dambo – Recycled Art and Troll Sculptures Trollmap – Locations of Thomas Dambo's Trolls Won't You Be My Neighbor? (2018 Documentary)

This Week in Health IT
Keynote: Don't be the Hero, Be a Pro - AI and Tech Governance with Chris Harper

This Week in Health IT

Play Episode Listen Later Jul 17, 2025 32:53 Transcription Available


July 17, 2025: Chris Harper, CIO and Senior Associate Vice Chancellor of AI at the University of Kansas Medical Center, discusses the nuances of AI governance. Chris discusses why he'd rather be "a pro than a hero" and how this philosophy shapes his collaborative leadership style in implementing AI solutions. They explore his organization's strategic technology bets over two decades, from meaningful use to data analytics to AI automation, and reveal how building trust with clinical partners has become the foundation for successful innovation. Through insights on governance across multiple organizational structures and his "move fast and be responsible" methodology, Chris offers practical wisdom for healthcare leaders preparing for what he sees as a paradigm shift in how technology will reshape the industry. Key Points: 03:55 Governance and Decision Making 10:33 Leadership and Team Collaboration 21:37 Disparities in Rural Areas 27:01 Challenges for Healthcare CIOs 30:01 Speed Round and Closing Remarks X: This Week Health LinkedIn: This Week Health Donate: Alex's Lemonade Stand: Foundation for Childhood Cancer

ASCO Guidelines Podcast Series
Therapy for Stage IV NSCLC Without Driver Alterations: ASCO Living Guideline Update 2025.1 Part 1

ASCO Guidelines Podcast Series

Play Episode Listen Later Jul 17, 2025 11:30


Dr. Lyudmila Bazhenova is back on the podcast to discuss the latest update of the living guideline on therapy for stage IV NSCLC without driver alterations. She shares the studies the Expert Panel reviewed in the first- and second-line settings, including NIPPON, HARMONi-2, and DUBLIN-3. Although these studies do not impact the existing guideline recommendations, Dr. Bazhenova provides context and comments on ongoing trials that will influence the next iteration of the living guideline. Read the full living guideline update “Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2025.1” at www.asco.org/thoracic-cancer-guidelines TRANSCRIPT This guideline, clinical tools, and resources are available at www.asco.org/thoracic-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-25-01062 Brittany Harvey: Hello, and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I'm interviewing Dr. Lyudmila Bazhenova from University of California San Diego Moores Cancer Center, co-chair on "Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2025.1." It's great to have you back on the show today, Dr Bazhenova. Dr. Lyudmila Bazhenova: It's my pleasure to be here. Brittany Harvey: And then before we discuss this guideline update, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Bazhenova, who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then to dive into the content here, Dr. Bazhenova, this living clinical practice guideline for systemic therapy for patients with stage IV non–small cell lung cancer without driver alterations is updated on an ongoing continuous basis. So what prompted this latest update to the recommendations? Dr. Lyudmila Bazhenova: Living ASCO guidelines are designed to keep pace with rapidly evolving evidence that impacts treatment of our patients with lung cancer. As a committee, we are tasked with regular review of the published literature and determine if the new data warrants changes to existing recommendations. So in this recently published update, we evaluated new trials related to treatment of patients with metastatic lung cancer without driver alterations. Brittany Harvey: Excellent. Thank you for that explanation of the process. So, you just mentioned that the panel reviewed new trials for this update. So, which particular updated evidence did the panel review on first-line treatment options for patients with good performance status across histology and PD-L1 expression status, and how did this impact the recommendations? Dr. Lyudmila Bazhenova: For the first-line treatment option for patients without driver alterations, two studies met our criteria for review. One was the NIPPON trial from Japan, the second was the HARMONi trial. None of those two trials resulted in change in our guidelines, but I think they are giving us some additional information that would be useful for the way we treat patients with non–small cell lung cancer without driver alterations. For example, if we take those patients, we currently have several treatment options as a first line. One is monotherapy immunotherapy. You can give pembrolizumab as an example, and that was based on the KEYNOTE-024 and KEYNOTE-042 trials. Then we have a platinum doublet plus immunotherapy, and there are several trials that did that pathway. And then we have also an option of giving our patients dual IO immunotherapy combination, such as CheckMate 9LA and POSEIDON. At this point, we do not have any randomized trials comparing those three treatment modalities head-to-head. And the NIPPON trial was interesting to us because it was the first trial to compare CheckMate 9LA regimen, which is again, dual immunotherapy plus chemo, versus KEYNOTE-189 or KEYNOTE-407, which is a chemotherapy plus immunotherapy. And as a result of the study, while chemotherapy plus ipilimumab-nivolumab led to numerically higher overall survival, the difference was not statistically significant. And what is concerning in that trial is that we saw a higher number of treatment-related death occurring in nivolumab and ipilimumab arm compared to the pembrolizumab-chemotherapy arm. As a matter of fact, the trial was terminated early because of the increased risk of death. If you look at the treatment-related death in CheckMate 9LA, the 9LA study reported the treatment-related death to be 2%, and then in the NIPPON trial, the treatment-related death was 7%. Why is that happening? It's really difficult to say. The study was done in Japan. Maybe there is some pharmacogenomic differences between global population and Japan population. But certainly the higher rate of adverse events needs to be taken into account. Another interesting thing about this trial is that it did not show any differences in a subset analysis for patients with squamous histology as well as PD-L1 negative tumor. So while this does not change our current guidelines and CheckMate 9LA treatment still remains an appropriate treatment option, it kind of raises the possibility that this combination could be associated with a higher toxicity. And we do have a randomized US-based trial that is ongoing, and we are hoping that eventually we will be able to answer that question after the trial will be completed. The second trial we reviewed is HARMONi-2. So HARMONi-2 was a randomized, double-blind study which is conducted primarily in China, looking at bispecific PD-L1 and VEGF antibody called ivonescimab. And that took patients who were PD-L1 positive, as defined as more than 1% expression, and patients were randomized to pembrolizumab versus bispecific ivonescimab. And the study was positive. It showed improvement in median progression-free survival of 11 months versus almost 6 months in bispecific versus pembrolizumab. There were, however, higher grade 3 events in the ivonescimab arm. At this point, we are not changing our recommendations because this trial was done in an ex-US population, and we are awaiting a similar trial ongoing in the United States before we change recommendations and decide if ivonescimab needs to be included in our guidelines. Brittany Harvey: This context is very helpful when clinicians think through the data behind these options. And it's important that the panel reviews this evidence, even if it doesn't prompt a change to the recommendations. And we'll await results of those trials that you mentioned to further inform this guideline. So then beyond those studies for first line, what updated evidence did the panel review for second-line and subsequent treatment options for patients with good performance status, and how did this impact the recommendations? Dr. Lyudmila Bazhenova: So for second line, only one trial met the criteria, and that was DUBLIN-3. DUBLIN-3 is a phase 3 single-blind randomized trial comparing docetaxel versus docetaxel plus plinabulin. And the study enrolled patients with second or third line. They have to have had platinum-based chemotherapy and progressed. Plinabulin is an interesting compound. It's a small molecule tubulin binder that prevents polymerization of tubulin and appears to impact dendritic cell maturation and T-cell activation. This study enrolled 559 patients, randomly assigned them to two groups. And one important information about this study is that was a study that was envisioned before immunotherapy became a standard mainstream treatment for first-line therapy. And only 20% of patients had prior PD-1 exposure. So therefore, the results of that study need to be taken into context of this population no longer existing in the United States because we use PD-L1 inhibitors in the first line. And we saw that interesting in the plinabulin arm had lower rates of neutropenia but higher rates of serious adverse events. And at this point, we are not changing our guidelines for mainly two reasons. Number one, low number of patients that received prior treatment with first-line immune checkpoint inhibitors, as well as a modest overall survival benefit of this trial. Brittany Harvey: Understood. I appreciate you describing that study as well and why that evidence didn't prompt a change to those particular recommendations. So then, what should clinicians know as they implement this living guideline, and how does this new evidence impact clinicians and patients? Dr. Lyudmila Bazhenova: At this point, none of the studies that we reviewed resulted in a change in guidelines. We are still waiting for more global results from some of the studies that I highlighted. It shows that there's still a lot of questions we need to be answering in those patients. And I'm hoping that with future clinical trials, we will be able to definitively maybe recommend one treatment over another. But at this point, all the treatments that I mentioned before remain appropriate for patients with stage IV non–small cell lung cancer without driver alterations. Brittany Harvey: Definitely. And then you just mentioned that there's still a lot of outstanding questions in this field. You've mentioned a couple different studies where we're awaiting evidence. Beyond those that you already mentioned, what is the panel examining for future updates to this living guideline? Dr. Lyudmila Bazhenova: Right now, our next task is to come up with a full guidelines update. ASCO have certain rules for the guidelines committee members. And so we are gearing for a full guideline update, which hopefully will be ready by the end of 2025. Brittany Harvey: Excellent. We'll look forward to that full update of the living guideline, and we'll still await results of these ongoing trials to further inform this living guideline. So I want to thank you so much for your work to rapidly and continuously update this living guideline, and thank you for the time today, Dr. Bazhenova. Dr. Lyudmila Bazhenova: My pleasure. Brittany Harvey: And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/thoracic-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you've enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Marietta Daily Journal Podcast
Marietta School Board to consider vape detection, substitute teacher funding

Marietta Daily Journal Podcast

Play Episode Listen Later Jul 16, 2025 7:51


MDJ Script/ Top Stories for July 16th Publish Date:  July 16th    Commercial: From the BG Ad Group Studio, Welcome to the Marietta Daily Journal Podcast.    Today is Wednesday, July 16th and Happy Birthday to Will Ferrell I’m Keith Ippolito and here are the stories Cobb is talking about, presented by Times Journal Marietta School Board to consider vape detection, substitute teacher funding Acworth Book & Storytelling Festival is Aug. 23 Letter shows Cobb's threat to halt police services in Mableton All of this and more is coming up on the Marietta Daily Journal Podcast, and if you are looking for community news, we encourage you to listen and subscribe!  BREAK: INGLES 3 STORY 1: Marietta School Board to consider vape detection, substitute teacher funding The Marietta Board of Education is set to discuss installing Halo vape detection systems in Marietta High, Middle, and Woods-Wilkins Campus. These devices, costing up to $60,000 funded by grants, discreetly monitor air quality, alerting staff to harmful chemicals like nicotine. Superintendent Grant Rivera and his team aim to tackle vaping issues proactively. Additionally, the board will consider a $2.4M contract with Kelly Services for substitute staffing and appointing R.K. Redding Construction for Marietta High renovations, scheduled for summers 2026-2027, funded by SPLOST. STORY 2: Acworth Book & Storytelling Festival is Aug. 23 The Acworth Book & Storytelling Festival is set for Aug. 23, 10 a.m. to 3 p.m., at The Roberts School in Acworth. Hosted by Acworth Cultural Arts, this free event features local and regional authors, professional storytellers, vendors, and a panel discussion themed “Ink & Echo: Writing the stories. Speaking the truth.” Keynote speaker Bren McClain, author of *One Good Mama Bone*, will join T.M. Brown in conversation. STORY 3: Letter shows Cobb's threat to halt police services in Mableton Mableton officials agreed to pay Cobb County $9.5 million for police and transportation services after the county threatened to halt them by June 1. Mayor Michael Owens said the city was forced into the deal to ensure public safety, despite concerns of "double taxation" for residents already paying county taxes. The agreement funds services until May 2026, with Mableton exploring a special service district to cover costs. While Cobb County claimed it wouldn’t abandon residents, a May 30 letter revealed threats to cease services if no deal was reached. The city council initially rejected the plan but later approved it after mediation. We have opportunities for sponsors to get great engagement on these shows. Call 770.799.6810 for more info.  We’ll be right back. Break: INGLES 3 STORY 4: Austell approves 158% property tax increase The Austell City Council approved a 158% property tax increase, raising the millage rate from 3.25 to 8.25 mills, despite strong opposition from residents. The hike, expected to double property tax revenue to $3.85 million, aims to stabilize finances and address a $1.6 million budget shortfall. Mayor Ollie Clemons defended the decision as necessary for the city’s future, while critics, including Council member Meredith Adams, opposed the sharp increase, citing its impact on residents, especially those on fixed incomes. Many residents blamed city leadership for financial mismanagement, while Clemons attributed the issues to inflation and past inaction. STORY 5: Cobb Water Authority manager talks fluoride, forever chemicals, costs Cole Blackwell, general manager of the Cobb County-Marietta Water Authority, emphasized proactive planning for water quality, affordability, and infrastructure reliability during a Kiwanis Club talk. The authority, sourcing water from Lake Allatoona and the Chattahoochee River, is addressing emerging contaminants like PFAS, though current levels remain safe. Inflation and rising construction costs have impacted operations, but costs are stabilizing, and the authority has a water supply sufficient through 2055. Blackwell reassured residents of continued fluoride use, compliance with regulations, and efforts to maintain reasonable water rates while ensuring future reliability. Break: STORY 6: Marietta man charged with stealing from Ford Elementary School Jamie Jr. Cline, 44, of Marietta, faces two theft charges for allegedly stealing a trailer and hay blower from Ford Elementary School in Acworth during separate incidents on June 29 and 30. According to police, Cline accessed the school by opening chained gates. Arrested on July 8, he was booked into the Cobb County Adult Detention Center and released the next morning on a $35,000 bond. STORY 7: Shaw Park Community Block Party is July 19 The Shaw Park Community Block Party will take place on July 19, from 11 a.m. to 1 p.m., at Gritters Library in Marietta. Hosted by Gritters Library, CobbWorks, and Cobb PARKS, this free, family-friendly event features a live DJ, inflatable games, face painting, bilingual storytime, and a Bollywood Dance Challenge. Food will be available for purchase from The Patty Wagon and King of Pops. The event aims to bring the community together and highlight local resources while celebrating the library’s recent reopening. We’ll have closing comments after this. Break: INGLES 3 Signoff-   Thanks again for hanging out with us on today’s Marietta Daily Journal Podcast. If you enjoy these shows, we encourage you to check out our other offerings, like the Cherokee Tribune Ledger Podcast, the Marietta Daily Journal, or the Community Podcast for Rockdale Newton and Morgan Counties. Read more about all our stories and get other great content at www.mdjonline.com Did you know over 50% of Americans listen to podcasts weekly? Giving you important news about our community and telling great stories are what we do. Make sure you join us for our next episode and be sure to share this podcast on social media with your friends and family. Add us to your Alexa Flash Briefing or your Google Home Briefing and be sure to like, follow, and subscribe wherever you get your podcasts. Produced by the BG Podcast Network Show Sponsors: www.ingles-markets.com See omnystudio.com/listener for privacy information.

Health Is the Key
Keynote: Take a Deep Breath

Health Is the Key

Play Episode Listen Later Jul 16, 2025 4:22


In our July replay episode, Dr. Karinn Glover, an Assistant Professor of Psychiatry at the Albert Einstein College of Medicine, explored burnout, the unique stressors that healthcare workers face and resources that can help. In our July Key Note, Dr. Glover discusses the role empathy plays – tuning into others' feelings as well as our own – in building supportive relationships that are key to battling burnout.  The Takeaway  We want to hear from you! Please complete our survey: 1199SEIUBenefits.org/member-feedback   Drop us a line at our social media channels: Facebook // Instagram // YouTube.  Find a mental health therapist through the Benefit Funds' Provider Directory: www.1199SEIUBenefits.org/find-a-provider   Connect with a therapist online through Teladoc: www.Teladoc.com or (800) TELADOC (835-2362).    Visit the Healthy Minds section of our Healthy Living Resource Center for additional information and resources: www.1199SEIUBenefits.org/healthyminds    For additional support, call our Wellness Member Assistance Program: (646) 473-6900.    Contact our partners at the National Alliance on Mental Illness (NAMI) for a wide variety of community resources: www.naminycmetro.org .    Reach out to the New York State Office of Mental Health Emotional Support Helpline at (844) 863-9314.  Guest Bio    Karinn Glover, MD, MPH, is an Assistant Professor of Psychiatry at the Albert Einstein College of Medicine, where she teaches psychopharmacology and aspects of psychotherapy to Psychiatry and Family Medicine residents. Her decade-plus experience as a psychiatrist and leader in the practice of integrated care and workplace mental health has informed her approach to health equity, Diversity, Equity, Inclusion and Belonging (DEI+B), and the styles of leadership that produce organizational success. Dr. Glover attended SUNY Downstate College of Medicine and obtained a Master of Public Health from Columbia University's Mailman School of Public Health via the highly competitive Macy Scholars Program. 

MacMost - Mac, iPhone and iPad How-To Videos
Master These 5 Basic Keynote Animations (MacMost #3316)

MacMost - Mac, iPhone and iPad How-To Videos

Play Episode Listen Later Jul 14, 2025


View this video at https://macmost.com/master-these-5-basic-keynote-animations.html. Learn how to go beyond basic Keynote transitions with animations that move objects on your slides. You can use builds, movement paths, scaling, rotation and Magic Move to create a variety of effects to push your presentation to the next level.

Restaurant Unstoppable with Eric Cacciatore
1201: Evan LeRoy, Chef and Co-Owner of LeRoy and Lewis

Restaurant Unstoppable with Eric Cacciatore

Play Episode Listen Later Jul 14, 2025 99:46


Evan LeRoy is a Co-Owner at LeRoy and Lewis in Austin, TX. Evan was featured on the show back in 2018 for episode 582. Back then, LeRoy and Lewis was a food truck that began in 2017, a year prior. The brick and mortar LeRoy and Lewis opened in February of 2024. This year, the restaurant won a Michelin star!  Join the Restaurant Unstoppable Network TODAY! Restaurant Unstoppable - EVOLVE! - Eric of Restaurant Unstoppable is now taking consultation and coaching calls! Book a consultation today! Schedule your call to become UNSTOPPABLE! Check out the website for more details: https://www.restaurantunstoppable.com/evolve Today's sponsors: Franchise Law Solutions - Thinking about franchising your restaurant? Success doesn't have to mean 100 units overnight. With the right plan, you can build a profitable, local or regional franchise brand. The team at Internicola Law Firm — franchise lawyers and franchise development experts — will show you how.  Visit www.franchiselawsolutions.com. US Foods: US Foods is hosting the event of the year, Food Fanatics 2025. August 19-20, 2025, at the Mandalay Bay, Las Vegas, NV. Network with over 5,000 Industry peers. Attend Zouk nightclub reception, expert breakout sessions, Keynote speeches, musical performances, and dramatic demonstrations, and sample the latest on-trend dishes. The Clock Is Ticking! Be Ready to Register on April 16 for Food Fanatics® 2025. To learn more, visit www.usfoods.com/foodfanatics2025 Restaurant Systems Pro - Join the 60-day Restaurant Systems Pro FREE TRAINING. This is something that has never been done before. This 60-day event is at no cost to you, but it is not for everyone. Fred Langley, CEO of Restaurant Systems Pro, will lead a group of restaurateurs through the Restaurant Systems Pro software and set up the systems for your restaurant. During the 60 days, Fred will walk you through the Restaurant Systems Pro Process and help you crush the following goals: Recipe Costing Cards; Guidance in your books for accounting; Cash controls; Sales Forecasting(With Accuracy); Checklists; Budgeting for the entire year; Scheduling for profit; More butts in seats and more… Click Here to learn more.  Let's make 2025 the year your restaurant thrives. Today's gues recommends:  Toast Sling Guest contact info:  Instagram: @evanleroybbq Instagram: @leroyandlewis YouTube: https://www.youtube.com/@ChudsBbq YouTube: https://www.youtube.com/@LeRoyandLewisBBQ Thanks for listening! Rate the podcast, subscribe, and share!  We are on Youtube: @RestaurantUnstoppable

Outils du Manager - Tout ce que vous avez toujours voulu savoir sur le management sans jamais oser le demander !

Pour aller plus loin et découvrir la méthode PPEC - Prises de Parole Efficaces et Captivantes, clique ici : https://www.formactions.outilsdumanager.com/ppec-inscription-mail-2***Découvre ce que nous avons créé pour t'aider à aller plus loin :Des formactions pratiques et concrètes pour manager efficacement, quel que soit ton rôle ou ton secteur.Une communauté unique en ligne, le CIEL, où dirigeants et cadres dirigeants, s'entraident pour réussir ensemble.L'offre exclusive du moment pour t'aider à passer à l'action dès aujourd'hui.Clique ici pour explorer le catalogue ODM : https://www.formactions.outilsdumanager.com/cataloguecomplet***

Capitol Weekly Podcast
Senator Scott Wiener: California and AI

Capitol Weekly Podcast

Play Episode Listen Later Jul 14, 2025 50:40


On July 8, Capitol Weekly and the University of California Student and Policy Center presented California and AI, a daylong look at the Golden State's approach to regulating Artificial Intelligence. California is a global leader in AI technology and lawmakers in Sacramento are tasked with creating legislation and regulations that will help the state maintain leadership in this emerging industry, while creating guardrails that protect Californians. Legislators have introduced over 30 AI-related bills this session, and nearly 20 AI bills were signed into law by Governor Newsom in 2024. Senator Scott Wiener led the charge both this year and last, and has emerged as one of the key voices in the discussion around AI regulation, and we present his Keynote as part of today's podcast. His remarks begin at about the 16 minute mark.1:48 Mecha-Hitler3:15 Op-Eds12:25 Remembering George Steffes15:58 Senator Scott Wiener42:23 #WWCAWant to support the Capitol Weekly Podcast? Make your tax deductible donation here: capitolweekly.net/donations/Capitol Weekly Podcast theme is "Pickin' My Way" by Eddie Lang"#WorstWeekCA" Beat provided by freebeats.io

TopSoil
Millennial Farmer Keynote | Zach Johnson Shares His Story at the TopSoil Summit 2025

TopSoil

Play Episode Listen Later Jul 14, 2025 37:47


At the 2025 TopSoil Summit, Zach Johnson, better known to his 1 M+ followers as the Millennial Farmer, delivered a powerful and personal keynote. Zach shared stories from his life on the farm, explained why he's passionate about agriculture, and emphasized the importance of helping the public understand what farmers do and why.A 6th-generation farmer, Zach blends old-school work ethic with a love for modern ag tech. His wit, honesty, and passion for bridging the gap between farmers and consumers made this one of the most memorable keynotes of the Summit.

TopSoil
Geoff Cooper Keynote: Farmers & Biofuels – A Time-Tested Connection | TopSoil Summit 2025

TopSoil

Play Episode Listen Later Jul 14, 2025 44:37


Geoff Cooper, President & CEO of the Renewable Fuels Association, kicked off Continuum Ag's TopSoil Summit with a powerful keynote: “Farmers & BioFuels: A Time-Tested Connection.”In his presentation, Geoff explored the longstanding partnership between agriculture and the biofuels industry, sharing timely insights on:✅ The current state of renewable fuels✅ Updates from Washington, D.C., including the latest on Section 45Z✅ Market trends in the Renewable Fuel Standard, trade opportunities, and global biofuel demandWith decades of experience and policy leadership, Geoff offered a compelling look at where the biofuels industry stands today and where it's headed next.

Personal Brand Story I Share your Story
Du bist nicht deine Geschichte, aber deine Geschichte kann dein größtes Kapital sein

Personal Brand Story I Share your Story

Play Episode Listen Later Jul 12, 2025 13:11


In dieser besonderen Solo-Folge spreche ich über ein Thema, das mir persönlich sehr am Herzen liegt: Wie du deine Geschichte erzählen kannst ohne dich von ihr beherrschen zu lassen.Vielleicht hast du etwas erlebt, das dich verändert hat, eine Krankheit, ein Verlust, eine Krise oder ein Neuanfang. All das gehört zu deiner Geschichte. Aber: Du bist nicht deine Geschichte. Du bist das, was du daraus gemacht hast.Ich nehme dich mit auf meine ganz eigene Reise, von der ersten öffentlichen Erzählung meiner Insolvenz über neue Perspektiven bis hin zu meiner Keynote bei einer Fuck-up Night. Und ich teile, wie ich meine Erfahrungen als Teil meiner Personal Brand in meine heutige Arbeit eingebunden habe.Deine Geschichte kann dein größtes Kapital sein.Erfahre in dieser Folge:Warum es so heilsam ist, die eigene Geschichte aus verschiedenen Blickwinkeln zu betrachtenWie du deine Erfahrungen nutzen kannst, um Vertrauen aufzubauen.Was eine starke Personal Brand Story ausmacht.Welche Fragen dir helfen, deine eigene Geschichte zu formulieren."Deine Geschichte ist kein Makel. Sie ist ein Geschenk."Hör rein und finde heraus, wie deine Geschichte dir Kraft geben kann – für dich, für dein Business und für die Menschen, denen du helfen willst.Teile die Folge gerne mit Menschen, die ihre Geschichte besser verstehen oder erzählen möchten.Mehr von mir findest du hier:Deine GeschichteLebensgeschichten VerlagMeine GeschichteVerpasse keine meiner Podcast Folgen und abonniere meinen Podcast auf Spotify oder itunesHat dir die Folge gefallen? Dann würde ich mich sehr freuen, wenn du meinen Podcast bewertest Vernetze dich mit mir auf LinkedIn.Hier geht's zu den Shownotes Support the show

Men in the Arena Podcast
Into the Storm: Jim Ramos' Man Camp 2025 Keynote EP 878

Men in the Arena Podcast

Play Episode Listen Later Jul 11, 2025 36:01


Are you a man who runs from the storm… or one who charges into it with trust and grit? What kind of man faces the storm—and what kind of Savior still calms it?  In this powerful message from Men in the Arena ManCamp 2025, Jim Ramos challenges men to stop shrinking back and start stepping up when life gets rough. Drawing from Mark 4 and the raw reality of personal trials, this talk explores what it means to trust Jesus in the middle of the storm—when the waves are high, your strength is gone, and all you've got left is faith. This is a challenge for every man to listen to the voice of Jesus, fix his eyes on the cross, and become the kind of man who heads into the storm instead of running from it. This episode is sponsored by Kids Outdoor Zone, an outdoor ministry for the men in your church. Watch your men come alive as they pass on their outdoor skills to the fatherless children in your church. Get your Outdoor Ministry Guide, and KOZ's World Famous Meat Rub, at kidsoutdoorzone.com/arena. This episode is sponsored by MTNTOUGH Fitness Lab, a Christian-owned fitness app. Get 6 weeks free with the code ARENA30 at MTNTOUGH.com. Every man needs a locker room. Join a brotherhood of like-minded men in The Locker Room, our bi-monthly live Zoom Q&A call! We meet in the Locker Room twice a month for community, fellowship, laughter, and to help each other find biblical answers to life's difficult questions. Sharing community with these amazing men is one of the most enjoyable things I do. - Jim Ramos https://patreon.com/themeninthearena Get Jim Ramos' USA TODAY Bestselling book, Dialed In: Reaching Your Full Capacity as a Man of God (https://tinyurl.com/dialedinbook)

Restaurant Unstoppable with Eric Cacciatore
1200: Jason Carrier, Owner of Mama Betty's Tex Mex

Restaurant Unstoppable with Eric Cacciatore

Play Episode Listen Later Jul 10, 2025 139:35


Jason Carrier is the owner of Mama Betty's Tex Mex located in North Austin, TX. Jason began hospitality his career in his early 20s working as a door man for bars in Austin. He loved the job, treating the position like a gracious host instead of an intimidating bouncer, and eventually went on to open his first bar in 2002, and at least 11 bars at various times. In 2020, he owned 5 bars that all shut down during the pandemic and decided to take over a restaurant space right in his neighborhood and turn it into a Tex Mex bar and restaurant. That was (and is) Mama Betty's Tex Mex!  Join the Restaurant Unstoppable Network TODAY! Restaurant Unstoppable - EVOLVE! - Eric of Restaurant Unstoppable is now taking consultation and coaching calls! Book a consultation today! Schedule your call to become UNSTOPPABLE! Check out the website for more details: https://www.restaurantunstoppable.com/evolve Today's sponsors: Franchise Law Solutions - Thinking about franchising your restaurant? Success doesn't have to mean 100 units overnight. With the right plan, you can build a profitable, local or regional franchise brand. The team at Internicola Law Firm — franchise lawyers and franchise development experts — will show you how.  Visit www.franchiselawsolutions.com. US Foods: US Foods is hosting the event of the year, Food Fanatics 2025. August 19-20, 2025, at the Mandalay Bay, Las Vegas, NV. Network with over 5,000 Industry peers. Attend Zouk nightclub reception, expert breakout sessions, Keynote speeches, musical performances, and dramatic demonstrations, and sample the latest on-trend dishes. The Clock Is Ticking! Be Ready to Register on April 16 for Food Fanatics® 2025. To learn more, visit www.usfoods.com/foodfanatics2025 Restaurant Systems Pro - Join the 60-day Restaurant Systems Pro FREE TRAINING. This is something that has never been done before. This 60-day event is at no cost to you, but it is not for everyone. Fred Langley, CEO of Restaurant Systems Pro, will lead a group of restaurateurs through the Restaurant Systems Pro software and set up the systems for your restaurant. During the 60 days, Fred will walk you through the Restaurant Systems Pro Process and help you crush the following goals: Recipe Costing Cards; Guidance in your books for accounting; Cash controls; Sales Forecasting(With Accuracy); Checklists; Budgeting for the entire year; Scheduling for profit; More butts in seats and more… Click Here to learn more.  Let's make 2025 the year your restaurant thrives. Today's gues recommends:  Toast OpenTable SpotHopper HotSchedules Kaizan Marketing Restaurant365 Guest contact info:  Website: https://www.ilovemamabettys.com Instagram: @mama.bettys Email: jason@carrier5.com Thanks for listening! Rate the podcast, subscribe, and share!  We are on Youtube: @RestaurantUnstoppable

This Week in Health IT
Keynote: The Great CIO Musical Chairs - Interim Leadership with Chris Scanzera and Judy Kirby

This Week in Health IT

Play Episode Listen Later Jul 10, 2025 36:47


July 10, 2025: Christopher Scanzera, Interim CIO at Lurie Children's Hospital, and Judy Kirby, Executive Recruiter at Kirby Partners, join Bill for a discussion around interim roles. With 53% of sitting healthcare CIOs having been in their roles for only three years, what Bill dubs “the great CIO musical chairs,” the conversation dives into the critical differences between interim and permanent leadership roles. What unique qualities does an interim leader need to succeed when they have just weeks, not months, to build relationships and drive results? The conversation explores what it really takes to transition from interim to permanent leadership in today's rapidly evolving technology landscape. Key Points: 01:21 The Interim Leadership Landscape 07:24 Building Organizational Alignment 25:11 Compensation and Workload for Interim CIOs 28:40 Preparing for Full-Time CIO Role X: This Week Health LinkedIn: This Week Health Donate: Alex's Lemonade Stand: Foundation for Childhood Cancer

ENA Podcast
Emergency Nursing 2025 Keynote Jeff Evans' Lessons From the Mountaintop

ENA Podcast

Play Episode Listen Later Jul 10, 2025 25:13


From the emergency department to the top of some of the world's tallest peaks, Jeff Evans has learned about leadership, teamwork and trust - and he's excited to share his stories and lessons learned in New Orleans when he keynotes Emergency Nursing 2025. Jeff joins the ENA Podcast to offer a taste of his experiences and why emergency nurses are "his people."

She Chose Joy with Melanie
Birth of Adventure Girl - LeeAnn Marie Webster

She Chose Joy with Melanie

Play Episode Listen Later Jul 10, 2025 55:17


LeeAnn shares the importance of finding joy in simple things, the healing power of storytelling, and how embracing emotions can lead to a more fulfilling life. LeeAnn sharesher journey of creating a one-woman show, the birth of her 'Adventure Girl' persona, and the significance of taking risks. They also delve into the concept of collecting regrets as a means to fuel future growth and the practice of gratitude and presence in everyday life. More about LeeAnn Marie Webster LeeAnn Marie Webster is the creator of No Regrets Formula™and host of the Full Self Expression Forum. She is an attorney turned international Keynote speaker, Moth Story Slam winner, and entrepreneur with 20 years' experience in marketing and business development in a range of industries. LeeAnn has a substantial event background, having successfully produced 130+ virtual summits and founding the largest speed dating company in Southern California. Her entrepreneurial journey started when she became the first person to host a speed dating event outside of the Jewish community, ultimately creating the largest speed dating company in Southern California (“Rapid Dating”).Her first national TV appearance was as a contestant on MTV's Remote Control. Since then, her entrepreneurial insights have been featured in NBC, The Huffington Post, The Los Angeles Times, and dozens more. Through her No Regrets Formula, she helps women leaders find a deeper sense of connection to themselves in order to feel more engaged, increase confidence, and live a more joyful life. She is also the creator of Fancy Meeting Me Here, her inspirational one woman show. Connect with LeeAnnhttps://RegretReleaseMethod.comLinkedin.com/in/leeannmariewebsterInstagram: @leeannmwebster A Moment of Gratitude for our sponsor.⁠ Michele AikenConnect with Melanie⁠⁠Work with Melanie ⁠⁠⁠⁠Download Joy Journal⁠⁠⁠⁠Radical Love Book

Der Bewohnerfrei Podcast mit Tobias Beck
#884 Der Weg aus der Unsichtbarkeit: Ein Blick durch das Mikroskop | Franz Gießibl

Der Bewohnerfrei Podcast mit Tobias Beck

Play Episode Listen Later Jul 8, 2025 15:43


In dieser inspirierenden Keynote nimmt uns Franz mit auf seine Reise vom unsichtbares Teilchen, zum internationalen Erfolg.   Ständig mit seinen Brüdern verwechselt, entwickelte er früh das Gefühl, unsichtbar zu sein. Der Wunsch, das Unsichtbare sichtbar zu machen, wuchs immer mehr. Diese Faszination führte ihn durch einen lebensverändernden Anruf zu einer Karriere in der Quanten-Nanohysik, in der er die Sichtbarkeit der kleinsten Teilchen erkundete. Doch kurze Zeit später bekam Franz eine bahnbrechende Idee.   Diese Keynote lädt dazu ein, die Schönheit des Unsichtbaren zu entdecken und das Potenzial in jedem von uns zu erkennen.   Lass dich inspirieren und erwecke auch deine Wünsche zum Leben.   ----------------------   BESUCHE FRANZ AUF:  Wikipedia: https://en.wikipedia.org/wiki/Franz_Josef_Giessibl FRANZ'S ERFINDUNG: https://qplussensor.com/   ---------------------   WARTELISTE KILLER KEYNOTE BOOTCAMP 2026: Bring deine Botschaft auf die Bühne und kreiere deine eigene Keynote:  https://www.tobias-beck.com/kkb/    ----------------------   SICHERE DIR TÄGLICHE INSPIRATION IN 2025 ➡️ Tritt jetzt der neuen Telegram Community bei: tobias-beck.com/telegram   STARTE DEINE AUSBILDUNG BEI TOBIAS BECK ➡️ Lass dich jetzt unverbindlich beraten: tobias-beck.com/mentor    

RIMScast
Risk and Clarity with Huw Edwards, RIMS Texas Keynote

RIMScast

Play Episode Listen Later Jul 8, 2025 34:04


Welcome to RIMScast. Your host is Justin Smulison, Business Content Manager at RIMS, the Risk and Insurance Management Society.   Justin interviews Huw Edwards, an entrepreneur, investor, and international speaker. Huw will kick off the RIMS Texas Regional Conference 2025 with his keynote speech. Huw covers the varied topics of leveraging his quantitative training in risk roles, his cybersecurity experience in the companies he helped develop, and even his extensive ultramarathon experience. Huw explores what entering the “pain cave” as an ultramarathon runner has taught him about life and risk management.   Huw believes that being AI-first will be a key factor in whether risk professionals will be promoted. He shares a preview of his keynote and his advice to risk professionals. Listen to learn about the role of quantitative analysis in entrepreneurship and risk management, and how risk management is evolving with AI tools.   Key Takeaways: [:01] About RIMS and RIMScast. [:17] About this episode of RIMScast. Our guest today is Huw Edwards, who will kick off the RIMS Regional Texas Conference 2025, which will be from August 4th through the 6th in San Antonio. [:44] Huw is a three-time business owner and an executive coach. We'll get a glimpse of his keynote today. [:51] RIMS-CRMP Workshops! The next Virtual RIMS-CRMP exam prep, co-hosted by Parima, will be held on September 2nd and 3rd. [1:02] The next RIMS-CRMP-FED virtual workshop will be led by Joseph Mayo on July 17th and 18th. Register by July 16th. Links to these courses can be found on the Certification Page of RIMS.org and through this episode's show notes. [1:20] RIMS Virtual Workshops! We have a day-long course on July 24th, “Risk Taxonomy for Effective Risk Management.” On August 5th, we have a day-long course about “Emerging Risks.” [1:32] We've launched a new course, “Intro to ERM for Senior Leaders.” This is a two-day course. The first two-day course will be held on August 12th and 13th and will be led by former RIMS President, Chris Mandel. [1:47] The course will be held again on November 4th and 5th and will be led by Elise Farnham. RIMS members enjoy deep discounts! [1:56] The full schedule of virtual workshops can be found on the RIMS.org/education and RIMS.org/education/online-learning pages. A link is also in this episode's notes. [2:07] If you tuned in to the recent episode featuring James Lam, you will know he is hosting a new six-module workshop for us, the “RIMS-CRO Certificate in Advanced Enterprise Risk Management”. [2:21] The inaugural summer course is completely sold out! We are filled to the virtual capacity! Don't worry, in the Fall, the bi-weekly course will begin on October 9th. Registration closes on October 2nd. A link is in this episode's notes. Check it out and register today! [2:40] Mark your calendars for November 17th and 18th for the RIMS ERM Conference 2025 in Seattle, Washington. The agenda is being built. Soon, we will distribute a Call for Nominations for the ERM Award of Distinction. I'll update this episode's show notes when that link is ready. [3:04] Think about your organization's ERM program or one you know of, and how it has generated value. We will have more on that in the coming weeks. [3:12] RISKWORLD 2026 will be in Philadelphia, Pennsylvania, from May 3rd through May 6th. RIMS members can now lock in the 2025 rate for a full conference pass to RISKWORLD 2026 when registering by September 30th. [3:26] This also lets you enjoy earlier access to the RISKWORLD hotel block. Register by September 30th, and you will also be entered to win a $500 raffle. Don't miss out on this chance to plan and score some extra perks. [3:39] The members-only registration link is in this episode's show notes. If you are not yet a member, this is the time to register at RIMS.org/membership. [3:49] On with the show! Our guest today is a Harvard- and Oxford-educated entrepreneur, investor, and international speaker. [3:57] On Tuesday, August 5th, he'll kick off the Inaugural RIMS Texas Regional Conference with his keynote, “Your Insurance Policy for Success: Eight Mental Toughness Lessons I've Learned from Running 100 Miles Through the Mountains.” [4:10] His name is Huw Edwards. He is the founder of multiple ventures, including Jungle Disk and CyberFortress. We're going to get a preview of his keynote and learn about his risk philosophies and risk journey. [4:21] Interview! Huw Edwards, welcome to RIMScast! [4:36] Huw is excited to be on RIMScast and to be opening the RIMS Texas Regional Conference in August. Justin loves going to Texas and is looking forward to the conference. [5:01] Huw comes from Wales. His accent comes from living in about 16 parts of the U.S. [5:55] Growing up, Huw was good with numbers. After college, being a mathematician, he landed a job with Goldman Sachs in a derivatives group. He helped big corporations manage their financial risks. [6:54] Huw tells about buying his first business. When he sold it, he didn't have the attachment of having founded it. He took it on a journey and then sold it to a private equity firm that joined it with several other companies to create a much bigger platform. [7:52] Huw is a “reluctant entrepreneur.” He was not a teenage businessman. He was good at school and at doing work. The first business he bought was a profitable going concern with existing customers. It was a business unit in a big company, stuck in a corner. [8:39] Huw saw it had wonderful economics and just had to be invested in. It had sticky customers. It was very profitable. It needed some love, care, and attention. That was Huw's easy transition into entrepreneurship. He bought the business in 2016. [9:00] In 2017, customers started asking where they could buy Bitcoin. Customers were asking about Bitcoin because they were victims of a ransomware attack that demanded Bitcoins to unlock their computers. Huw's company had backups of its clients' data. [10:00] This circumstance pulled the company into the world of cyber insurance. It was a new field. Huw's company served small businesses and helped them protect their data. Managing their clients' data, they realized they could do the job better. [10:53] Huw says two things connect him to the RIMS Texas Regional Conference. The Insurance Company, USAA, is in San Antonio. Another insurance company, Argo, was there for a time. In 2018, RISKWORLD was held in San Antonio. [11:30] In 2018, Huw and partners incubated an MGA within a large company. They showed up at RISKWORLD to do customer testing and exploration. Coming back to a RIMS conference as a keynote speaker is a full-circle journey for Huw. [12:11] Huw's company was CyberFortress. It was spun out from Jungle Disk, a larger company. Huw raised a bunch of VC money and swung for the fences, but didn't find a product market fit there. They had built a solution, looking for a problem. It was a character-building experience. [13:06] It gave Huw some great insight, working with the insurance company. They launched their insurance policy in Texas, backed by Markel. The challenge was that it wasn't well-positioned, and people didn't buy it. [13:29] Huw believes the greatest opportunity for risk managers in today's cybersecurity landscape is to understand that the big factor is human behavior. You can buy systems, but it comes down to the people running those systems. [13:52] The successful cyber insurance offerings and cybersecurity firms largely help, train, monitor, and guide behavior to avoid clients doing the dumb stuff. Don't click on dumb stuff. [14:14] Risk managers are now interested in AI. AI is just another very powerful tool that can give you a lot of leverage. You can't outsource responsibility to AI, but it can do a lot of things. You can leverage those things. [15:01] Companies are looking for employees who are AI-first. Your comfort with AI will be a deciding factor that separates the people who are promoted or kept on.  [16:12] Huw thinks risk managers get a bad rap. Huw worked for Bridgewater. When he took the job, he was given a lot of books on managing risk. He learned you're not trying to eliminate risk but trying to manage it. How do you take advantage of risk? How do you scale risk exposure? [16:59] How do you mitigate the catastrophic risk or existential risk that could kill, but be open to riding the waves of the lesser risks that could give great upsides? [17:18] Risk managers can be seen as Negative Nancy, saying no. But risk management can enable. [17:47] Huw will talk about his long-distance running. He is also a big Formula 1 fan. Formula 1 cars can go really fast. What makes the Formula 1 car go fast around the track is good brakes. Like brakes in a car, risk management can make something go faster, braking when needed. [18:55] Plugs with Roma Rishi, Sr. Sales Executive, Origami Risk! Origami Risk is excited to be a sponsor at the RIMS Texas Regional Conference. Origami Risk will have a booth there to demonstrate their products. They will also speak at one of the sessions. [19:35] They will be talking with Roy Hock, the Director of Excess Insurance at Valero Energy, about leveraging technology to manage your captive. See Origami at its table, at its session, or both! [19:48] Origami Risk will be at the RIMS Texas Regional Conference from August 4th through August 6th. Origami Risk will also be at the tenth Chicagoland Risk Forum, on September 18th at the Old Post Office in Chicago. [20:02] Origami Risk will have a booth there, and Roma's colleague, Gina Rothweiler, is going to be speaking. Come find Origami Risk at the Chicagoland Risk Forum! [20:10] Registration is complimentary for members of risk management departments in the nearby area. A link to the registration page is in this episode's show notes. You can visit ChicagoRIMS.org as well. [20:33] On October 1st through the 3rd, Origami Risk will be in the Bay Area, California, for the RIMS Western Regional Conference. They will have a booth and will speak at a session with the Risk Manager of Sprouts about leveraging data and technology for productive risk management. [21:02] Origami Risk will be at RIMS ERM, on November 17th and 18th in Seattle, Washington. That agenda is being built. Origami Risk will have a kiosk and hope to speak, too. [21:22] Origami Risk will have a presence at the 2025 Florida RIMS Educational Conference from July 29th through August 2nd. Connect with Roma's colleague Alex and Origami Risk there. [21:37] Roma, it's always great to see you and the Origami Risk team. [21:45] Connect with Roma and Origami Risk online at LinkedIn and OrigamiRisk.com, in the Contact Us area. [21:52] Let's Return to the Conclusion of My Interview with RIMS Texas Keynote Speaker Huw Edwards! [22:01] On Tuesday, August 5th, at 9:00 a.m., Huw Edwards will kick off the RIMS Texas Regional with his keynote address. He will talk about personal experiences, which include several ultramarathons.  [22:54] For Huw, it was the challenge and the uncertainty that drew him to ultramarathons. When you line up on the start line of a marathon, you might not know how well you'll do that day, but by and large, you know you'll finish. [23:40] Huw found himself drawn to these 100-mile races, in the mountains, going up and down, on trails, at altitude. It's an eating and hydration competition, and getting your electrolytes right. It's about managing the heat of the day and the cold of the night. [24:18] It's about your stomach going South, or rolling an ankle. You can have a belief on the start line that you will finish, but you don't know what's going to happen that day. It's a somewhat controlled, uncontrollable environment. It's less complex than risk management. [25:01] In risk management, you have hundreds of thousands or millions of human players and economic actors interacting. When you're running, you have yourself, knowing how hard you can push, but you don't know what the weather will bring. It's a microcosm of the game of life. [25:39] The lessons are huge. We somehow think we can control everything in life, or we try. In running this kind of distance, things just go wrong. You can't control everything, so how do you learn how to respond? That's what keeps Huw coming back to ultramarathons. [26:07] Justin sees the parallels with risk management; you're striving for greatness, but sometimes you have to settle for goodness. [26:27] You don't go all in from the start. You have to pace yourself. The races have a time cutoff. If you are too conservative, you won't get there. In risk management, if you try to mitigate all risk, you'll have to pay through the nose for insurance. It's a judgment call. [27:28] In ultramarathons, you navigate emotional highs and lows. No matter how you're feeling, good or bad, it won't last. When you're running great, enjoy it; it's not going to last. When you feel terrible, that will pass, too. [27:53] That's a glimpse of part of the keynote. Justin says it's great that Huw has risk experience and has been to RISKWORLD. [28:18] Huw has a theme, smiling on the outside, suffering on the inside. For a long time, he tried to put a brave face on things. It's OK to suffer at times, acknowledge it, and not paper over the cracks of your feelings. It's OK to be authentic. Huw will touch on that in the keynote. [28:54] Sometimes you learn a lot in those moments of suffering. Huw will talk about the pain cave. At some point in an ultramarathon, you enter the pain cave. This term was made famous by one of the greatest ultra runners, Courtney Dauwalter. [29:28] When Courtney Dauwalter talks about the pain cave, she says she used to try to push it off and delay the inevitable moment of going into the pain cave. But the whole point is to experience that edge. [29:48] So you welcome the pain cave. It was meant to hurt. What can we learn about it? [30:06] Huw will take questions at the end of his keynote. Everyone can go to the link in this episode's show notes for the registration page for the RIMS Texas Regional Conference. [30:18] Huw, it was such a pleasure to meet you! I can't wait to see you live on stage on August 5th. [30:29] Special thanks again to Huw Edwards for joining us here on RIMScast! He will be kicking off the RIMS Texas Regional Conference 2025. That's the Risk Management Roundup in San Antonio, Texas, from August 4th through August 6th. Huw will be there on August 5th. [30:48] Visit the Events page on RIMS.org and the link in this episode's show notes to register. [30:53] RIMS has negotiated a discounted rate at the Grand Hyatt San Antonio River Walk. The cutoff date for reservations is July 11th. So, register now and make those reservations! [31:06] Plug Time! You can sponsor a RIMScast episode for this, our weekly show, or a dedicated episode. Links to sponsored episodes are in the show notes. [31:34] RIMScast has a global audience of risk and insurance professionals, legal professionals, students, business leaders, C-Suite executives, and more. Let's collaborate and help you reach them! Contact pd@rims.org for more information. [31:52] Become a RIMS member and get access to the tools, thought leadership, and network you need to succeed. Visit RIMS.org/membership or email membershipdept@RIMS.org for more information. [32:10] Risk Knowledge is the RIMS searchable content library that provides relevant information for today's risk professionals. Materials include RIMS executive reports, survey findings, contributed articles, industry research, benchmarking data, and more. [32:26] For the best reporting on the profession of risk management, read Risk Management Magazine at RMMagazine.com. It is written and published by the best minds in risk management. [32:40] Justin Smulison is the Business Content Manager at RIMS. You can email Justin at Content@RIMS.org. [32:48] Thank you all for your continued support and engagement on social media channels! We appreciate all your kind words. Listen every week! Stay safe!   Links: RIMS Hurricane/Storm Risk Management Resource Center  RIMS Texas Regional 2025 — August 3‒5 | Registration open. RIMS-CRMP In-Person Workshop in Texas Aug. 6 & 7 RIMS 2025 Florida Educational Conference | July 31‒Aug 2 | Registration open. RIMS Canada 2025 — Sept. 14‒17 | Registration open! 10th Annual Chicagoland Risk Forum — Sept. 18 | Registration open! RIMS Western Regional — Oct 1‒3 | Bay Area, California | Registration open! RISKWORLD 2026 — Members-only early registration! Register through Sept 30! RIMS-Certified Risk Management Professional (RIMS-CRMP) The Strategic and Enterprise Risk Center Spencer Education Foundation — General Grants 2026 — Application Deadline July 30, 2025 RIMS ERM Conference 2025 — Nov 17‒18 in Seattle! [Save the Date!] RIMS-CRO Certificate in Advanced Enterprise Risk Management — Featuring Instructor James Lam! Summer course sold out! | Next bi-weekly course begins Oct 9. RIMS Diversity Equity Inclusion Council OrigamiRisk.com Huw Edwards — Career Clarity Coaching RISK PAC | RIMS Advocacy | RIMS Legislative Summit SAVE THE DATE — March 18‒19, 2026 RIMS Risk Management magazine | Contribute RIMS Now RIMS Webinars: RIMS.org/Webinars   Upcoming RIMS-CRMP Prep Virtual Workshops: RIMS-CRMP-FED Exam Prep Virtual Workshop — July 17‒18 RIMS-CRMP Exam Prep Virtual Workshop — Sept 2‒3, 2025 | Presented by RIMS and PARIMA Full RIMS-CRMP Prep Course Schedule “Risk Taxonomy for Effective Risk Management” | July 24 | Instructor: Joe Mayo “Emerging Risks” | Aug 5 | Instructor: Joe Mayo “Intro to ERM for Senior Leaders” | Aug. 12‒13 | Instructor: Chris Mandel “Intro to ERM for Senior Leaders” | Nov. 4‒5 | Instructor: Elise Farnham See the full calendar of RIMS Virtual Workshops RIMS-CRMP Prep Workshops   Related RIMScast Episodes: “James Lam on ERM, Strategy, and the Modern CRO” “ERM, Retail, and Risk with Jeff Strege” “Stacking Habits with Olympic Gold Medalist Jon Montgomery” “Financial Risk Management with Chris Willey of American Eagle FCU” “Applying ERM Theory with Elise Farnham” “Bigger Risks with the Texas State Office of Risk Management” | Sponsored By Hillwood “Exploring Risk in Extreme Environments with Kevin Vallely”   Sponsored RIMScast Episodes: “The New Reality of Risk Engineering: From Code Compliance to Resilience” | Sponsored by AXA XL (New!) “Change Management: AI's Role in Loss Control and Property Insurance” | Sponsored by Global Risk Consultants, a TÜV SÜD Company “Demystifying Multinational Fronting Insurance Programs” | Sponsored by Zurich “Understanding Third-Party Litigation Funding” | Sponsored by Zurich “What Risk Managers Can Learn From School Shootings” | Sponsored by Merrill Herzog “Simplifying the Challenges of OSHA Recordkeeping” | Sponsored by Medcor “Risk Management in a Changing World: A Deep Dive into AXA's 2024 Future Risks Report” | Sponsored by AXA XL “How Insurance Builds Resilience Against An Active Assailant Attack” | Sponsored by Merrill Herzog “Third-Party and Cyber Risk Management Tips” | Sponsored by Alliant “RMIS Innovation with Archer” | Sponsored by Archer “Navigating Commercial Property Risks with Captives” | Sponsored by Zurich “Breaking Down Silos: AXA XL's New Approach to Casualty Insurance” | Sponsored by AXA XL “Weathering Today's Property Claims Management Challenges” | Sponsored by AXA XL “Storm Prep 2024: The Growing Impact of Convective Storms and Hail” | Sponsored by Global Risk Consultants, a TÜV SÜD Company “Partnering Against Cyberrisk” | Sponsored by AXA XL “Harnessing the Power of Data and Analytics for Effective Risk Management” | Sponsored by Marsh “Accident Prevention — The Winning Formula For Construction and Insurance” | Sponsored by Otoos “Platinum Protection: Underwriting and Risk Engineering's Role in Protecting Commercial Properties” | Sponsored by AXA XL “Elevating RMIS — The Archer Way” | Sponsored by Archer   RIMS Publications, Content, and Links: RIMS Membership — Whether you are a new member or need to transition, be a part of the global risk management community! RIMS Virtual Workshops On-Demand Webinars RIMS-Certified Risk Management Professional (RIMS-CRMP) RISK PAC | RIMS Advocacy RIMS Strategic & Enterprise Risk Center RIMS-CRMP Stories — Featuring RIMS President Kristen Peed!   RIMS Events, Education, and Services: RIMS Risk Maturity Model®   Sponsor RIMScast: Contact sales@rims.org or pd@rims.org for more information.   Want to Learn More? Keep up with the podcast on RIMS.org, and listen on Spotify and Apple Podcasts.   Have a question or suggestion? Email: Content@rims.org.   Join the Conversation! Follow @RIMSorg on Facebook, Twitter, and LinkedIn.   About our guests: Huw Edwards, Entrepreneur, investor, and international speaker Roma Rishi, Sr. Sales Executive, Origami Risk   Production and engineering provided by Podfly.  

Looking at Lyme
68. New chronic Lyme research from the National Academies of Sciences, Engineering, and Medicine

Looking at Lyme

Play Episode Listen Later Jul 8, 2025 36:39


Hello, and welcome to season six of Looking at Lyme! We're thrilled to be kicking off this season talking with contributors of an important new research report from the National Academies of Sciences, Engineering and Medicine, which studied current gaps in research and treatments for Lyme Infection-Associated Chronic Illnesses.Dr. Kent Kester is board certified in both internal medicine and infectious diseases, is the chair of the publication committee, and is the vice chair of the National Academy of Medicine Forum on Microbial Threats. During his 24-year career in the U.S. Army, Kent led multiple research platforms at the biggest and most diverse lab with the Department of Defense, with a significant emphasis on emerging infectious diseases, and later led that institution as its commander.Nicole Malachowski is a retired air force fighter pilot, National Women's Hall of Famer, Keynote speaker, and Tick Borne Illness Patient Advocate. She lives and works in Colorado and she represents the patient perspective on the NASEM committee that produced this important new research.Their new publication is called “Charting a Path Toward New Treatments for Lyme Infection-Associated Chronic Illness”. (https://doi.org/10.17226/28578) We spoke with these two about their experiences putting together this report, and what impact they hope it will have moving forward.

The Brand Called You
Unlocking Powerful Keynote Performances: Carmen Sederino, Performance Master & Speaking Strategist

The Brand Called You

Play Episode Listen Later Jul 7, 2025 25:30


Unlock the secrets of unforgettable public speaking and performance with Carmen Sederino, a renowned Performance Master and Speaking Strategist from Melbourne, Australia! In this powerful episode of The Brand Called You, Carmen shares her remarkable journey from a shy child to a confident stage master, revealing how her background in theater shaped her unique Illuminated Story Method.Discover how to transform presentations into immersive keynote experiences, harness the power of storytelling, and engage audiences with emotion and impact. Carmen also gives practical advice on conquering stage fright, crafting memorable messages, and why you should ditch the PowerPoint slides for good!Whether you're a leader, entrepreneur, or aspiring speaker, this episode is packed with actionable strategies to help you own the stage and spread your message with confidence.

She Slays the Day
320 - Crafting a Keynote That Converts: Building Authority Through Speaking feat. Andrew Chesnutt

She Slays the Day

Play Episode Listen Later Jul 6, 2025 61:15


What does it actually take to deliver a compelling keynote—and get paid for it? If you've ever said “yes” to a speaking opportunity and then immediately panicked about what to say, this episode is for you. Dr. Lauryn sits down with keynote architect Andrew Chesnutt to unpack how to craft a powerful talk that creates real impact—and real business results. Whether you're dreaming of big stages or just want to clearly communicate your message, this conversation will give you the roadmap.Together, they explore Andrew's step-by-step framework for building a keynote from scratch, why your message matters more than your delivery, and how to avoid the common mistakes that kill momentum on stage. They also cover how to repurpose keynotes into social media and podcast content, why “authority by proximity” is your secret weapon, and how to turn your personal story into your most powerful sales tool.Key TakeawaysStructure Beats Spontaneity: A successful keynote follows a proven structure—from a strong hook to clear teaching points and a memorable close. Andrew outlines the blueprint for building a compelling talk that works every time.Find Your Unique Message: The best speakers aren't trying to say everything—they're focused on one mission, one audience, and one clear call to action. Andrew explains how to niche down without losing impact.Authority by Proximity Works: Sharing the stage or podcast mic with respected voices instantly elevates your own credibility. Learn how to use interviews, speaking, and podcasting as tools for building trust.Start Before You're Ready: Most entrepreneurs wait too long to speak. Andrew shares why you don't need a fancy bio to start—just a clear purpose and the willingness to get on stage.About the GuestAndrew Chesnutt is the founder of The Authority Forge, where he helps entrepreneurs, coaches, and experts turn their voice into influence through keynotes and podcasting. With nearly two decades of experience in the learning industry and a background in tech, Andrew has helped build two seven-figure businesses. Today, he's focused on helping 100,000 entrepreneurs craft messages that matter and deliver talks that convert. He's also the host of Hustle and Grind, a podcast exploring the origin stories of real entrepreneurs.Interested in working with Andrew? Check out The Authority ForgeEmail Andrew directly: andrew@theauthorityforge.comFollow Andrew: LinkedIn | Instagram Resources:Join The Uncharted CEO: An 8-week immersive experience for clinic owners designed to increase revenue, maximize profits, and build cash flow systems that create freedom NOW, not at 65. Founder's pricing spots are going fast, secure yours today!Join The Uncharted Collective: A Membership for Healthcare Professionals to Build a Profitable Personal Brand in Just 2 Hours a WeekFollow She Slays on YouTube to watch video versions of the show and get additional content!Sign up for the Weekly Slay newsletter!Follow She Slays and Dr. Lauryn:

AppleX4
¿Y si Apple empezara de cero? Que debería hacer.

AppleX4

Play Episode Listen Later Jul 6, 2025 88:33


¿Qué pasaría si Apple tuviera que empezar desde cero?En este episodio de AppleX4, el podcast en español sobre el mundo Apple y la tecnología, nos imaginamos un escenario radical: Apple desaparece… y somos nosotros quienes debemos reconstruirla. Rediseñamos el catálogo de productos, eliminamos las apps nativas que sobran, proponemos una nueva Keynote, y debatimos sobre el futuro de iPhone, iPad, Mac y todo el ecosistema Apple.Una charla divertida, honesta y con ideas que combinan experiencia real como usuarios con mucha creatividad.También compartimos cómo usamos nuestros dispositivos Apple en el día a día, desde iOS hasta macOS, y nos lanzamos a imaginar funciones nuevas que Apple todavía no ha implementado (pero debería). Todo sin filtros.Un episodio distinto, para fans de Apple, creadores, usuarios exigentes y curiosos de la innovación tecnológica.José → Soporte portátil para MacBookMiguel → SaferLayer – Gestor de contraseñasJosé Manuel → Luz de lectura LED con pinzaRedes sociales → @AppleX4_ (Instagram, TikTok, X y Threads)Telegram → AppleX4 comunidad Web oficial → www.applex4.com

Spiritual Misfits Podcast
The Future Church is Trans (Josephine Inkpin | FC Conference Keynote)

Spiritual Misfits Podcast

Play Episode Listen Later Jul 5, 2025 52:46


About This Series Over six weeks, we're sharing keynote talks and discussions from the second Future Church Conference, held at the Tram Sheds in Glebe. This gathering brought together church leaders, pastors, and Jesus-followers passionate about creating safer, more inclusive faith communities.Whether you're leading church, leaving church, unsure about the whole thing, or just curious about what the future might hold, these conversations explore what it means to reimagine church for everyone.Conference Posture Future Church Conference invited participants to adopt three key postures:Lean in - Sit with discomfort and ask why certain ideas trigger usListen - Hear vulnerable ideas from speakers and connect with each otherLook forward - Focus on future possibilities rather than past woundsWhat You'll Hear in This Episode:Josephine Inkpin's keynote on what it means to 'trans' the Church beyond gender alone. A powerful closing poem from Boy RenaissanceAbout the Speaker: Josephine Inkpin is a priest and activist, and a leading voice in Australia for LGBTQ+ inclusion in faith communities committed to a genuinely ecumenical approach. Want to reach out and let us know your thoughts or suggestions for the show? Send us a message here; we'd love to hear from you.The Spiritual Misfits Survival Guide (FREE): https://www.spiritualmisfits.com.au/survivalguideSign up to our mailing list:https://spiritualmisfits.com.au/Join our online Facebook community: https://www.facebook.com/groups/spiritualmisfitspodcastSupport the pod:https://spiritualmisfits.com.au/support-us/View all episodes at: https://spiritualmisfits.buzzsprout.com

MOM DOES IT ALL | Motherhood | Motivation | Self-love | Self-care | Mompreneurship | Energy | Mental Health | Fitness | Nutri

Join us as we explore the inspiring journey of Erin Herman, a dynamic keynote speaker who has turned her passion for change management and empowering women into a thriving career. Erin shares how a pivotal moment following her father's passing led her to reflect on her life's purpose, ultimately deciding to embrace her love for mentorship and impactful storytelling. From her experiences in successful careers to the serendipitous encounter with Kristen Hadid, Erin reveals how she seized opportunities and leveraged mentorship to build a successful keynote business. Her story underscores the importance of authenticity and courage in pursuing one's passion. Listen in as we discuss the challenges and triumphs of a leader within the UN system, who discovered empowerment and resilience through a mission-driven approach. By embracing the mantra of "mission, moment, message," Erin found strength in balancing a demanding travel lifestyle with family responsibilities. This episode also highlights the power of storytelling, as Erin recounts touching stories of audience members finding new beginnings and self-assurance through her keynotes. Don't miss out on the opportunity to stay connected with Erin's work and insights through her website and active presence on social media platforms.   Connect with Erin:Website: www.theerinherman.com LinkedIn: Erin Herman Instagram: @eebherm Facebook: Erin Beaton Herman TikTok: _erin111 Let's keep the conversation going!Website: www.martaspirk.com Instagram: @martaspirk Facebook: Marta Spirk Want to be my next guest on The Empowered Woman Podcast?Apply here: www.martaspirk.com/podcastguest  Watch my TEDx talk: http://bit.ly/martatedx Love cozy mysteries? Meet Nora Bardin, a lifelong puzzle solver turned author, who crafts fast-paced, feel-good whodunits. Her stories are packed with charm, suspense, and satisfying twists—whether you're fireside or on your lunch break. Escape into a world where justice always wins. Discover Nora Bardin's books now on Amazon: https://www.amazon.com/stores/Nora-Bardin/author/B0F3Y5BP4R  

Oncology Brothers
ASCO 2025 - GU Cancer Highlights: KEYNOTE-564, AMPLITUDE, ARANOTE, NIAGARA

Oncology Brothers

Play Episode Listen Later Jul 4, 2025 18:16


Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain, both practicing community oncologists, are joined by Dr. Tian Zhang from UT Southwestern to discuss key highlights from the ASCO 2025 annual meeting, focusing on genitourinary (GU) malignancies. Episode Highlights: • KEYNOTE-564: discussed 5 years OS data, reinforcing the role of adjuvant pembrolizumab in renal cell carcinoma • AMPLITUDE: combination of PARP inhibitor niraparib with abiraterone improved progression-free survival in patients with homologous recombination repair mutations in metastatic hormone-sensitive prostate cancer • ARANOTE: positive quality of life impact when using darolutamide in metastatic hormone-sensitive prostate cancer, which is also FDA approved now • NIAGARA: the prognostic value of ctDNA in muscle-invasive bladder cancer, emphasizing its implications for treatment strategies YouTube: https://youtu.be/Rt8HQpdyVY0 Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Join us as we break down these important studies and their potential to change clinical practice in oncology. Don't forget to check out our other episodes for more insights into cancer care!

iOS Today (Video HI)
iOS 759: iPad Accessories - From basic tablet to pro workstation!

iOS Today (Video HI)

Play Episode Listen Later Jul 3, 2025 45:08


Mikah and Rosemary visit the world of iPad accessories that can truly transform your tablet experience, from the game-changing Magic Keyboard to creative stands and essential styli that unlock your iPad's full potential! Magic Keyboard & Physical Keyboards Apple Magic Keyboard - Premium keyboard case adds trackpad, extra USB-C charging port, and robust protection while transforming typing workflows Budget alternatives - Logitech Keys-to-Go and other Bluetooth keyboards offer function keys and media controls at lower price points Travel benefits - Bluetooth keyboards with media keys provide convenient remote control for video streaming and presentations Customization & Protection Vinyl wraps - Slickwraps and dbrand offer protective skins in textures like carbon fiber, marble, leather effects, and retro designs Practical benefits - Wraps add grip, protection, and personalization while helping identify devices in groups Apple Pencil Ecosystem Apple Pencil Pro - Latest model features squeeze gestures for tool palettes, barrel roll rotation, haptic feedback, hover detection, and Find My support Model comparison - Pro vs 2nd generation vs USB-C vs 1st generation, with varying features and price points Stand Solutions Satechi aluminum desktop stand - Heavy-duty stand with cable management, dual orientation support, and flexible positioning from flat to upright Satechi hub stand - Premium desktop solution combining stand with 4K HDMI out, USB-A & USB-C ports, SD readers, and audio jack Twelve South HoverBar Duo - Versatile system with clamp and desktop bases, Apple Pencil storage, and robust articulating arm Specialty Accessories Satechi Bluetooth remote - Compact media controller supporting PowerPoint, Keynote, streaming apps, and presentation software iPad cushion/pillow - UGREEN's washable lap cushion with multiple viewing angles, storage pockets, and ergonomic positioning Shortcuts Corner Van's question - How to discover full folder paths in Save File shortcuts after creation, since interface only shows last selected location Mr. Met's inspiration - Wanted shortcut to open Safari's new tab page instead of getting distracted by previous tabs App Cap Adobe Project Indigo - Beta computational photography app using multiple exposures for enhanced dynamic range and noise reduction PopSocket MagSafe Grips - Magnetic phone grips with easy attachment/removal and swappable tops Hosts: Mikah Sargent and Rosemary Orchard Contact iOS Today at iOSToday@twit.tv. Download or subscribe to iOS Today at https://twit.tv/shows/ios-today Want access to the ad-free video and exclusive features? Become a member of Club TWiT today! https://twit.tv/clubtwit Club TWiT members can discuss this episode and leave feedback in the Club TWiT Discord.

iOS Today (MP3)
iOS 759: iPad Accessories - From basic tablet to pro workstation!

iOS Today (MP3)

Play Episode Listen Later Jul 3, 2025 45:08


Mikah and Rosemary visit the world of iPad accessories that can truly transform your tablet experience, from the game-changing Magic Keyboard to creative stands and essential styli that unlock your iPad's full potential! Magic Keyboard & Physical Keyboards Apple Magic Keyboard - Premium keyboard case adds trackpad, extra USB-C charging port, and robust protection while transforming typing workflows Budget alternatives - Logitech Keys-to-Go and other Bluetooth keyboards offer function keys and media controls at lower price points Travel benefits - Bluetooth keyboards with media keys provide convenient remote control for video streaming and presentations Customization & Protection Vinyl wraps - Slickwraps and dbrand offer protective skins in textures like carbon fiber, marble, leather effects, and retro designs Practical benefits - Wraps add grip, protection, and personalization while helping identify devices in groups Apple Pencil Ecosystem Apple Pencil Pro - Latest model features squeeze gestures for tool palettes, barrel roll rotation, haptic feedback, hover detection, and Find My support Model comparison - Pro vs 2nd generation vs USB-C vs 1st generation, with varying features and price points Stand Solutions Satechi aluminum desktop stand - Heavy-duty stand with cable management, dual orientation support, and flexible positioning from flat to upright Satechi hub stand - Premium desktop solution combining stand with 4K HDMI out, USB-A & USB-C ports, SD readers, and audio jack Twelve South HoverBar Duo - Versatile system with clamp and desktop bases, Apple Pencil storage, and robust articulating arm Specialty Accessories Satechi Bluetooth remote - Compact media controller supporting PowerPoint, Keynote, streaming apps, and presentation software iPad cushion/pillow - UGREEN's washable lap cushion with multiple viewing angles, storage pockets, and ergonomic positioning Shortcuts Corner Van's question - How to discover full folder paths in Save File shortcuts after creation, since interface only shows last selected location Mr. Met's inspiration - Wanted shortcut to open Safari's new tab page instead of getting distracted by previous tabs App Cap Adobe Project Indigo - Beta computational photography app using multiple exposures for enhanced dynamic range and noise reduction PopSocket MagSafe Grips - Magnetic phone grips with easy attachment/removal and swappable tops Hosts: Mikah Sargent and Rosemary Orchard Contact iOS Today at iOSToday@twit.tv. Download or subscribe to iOS Today at https://twit.tv/shows/ios-today Want access to the ad-free video and exclusive features? Become a member of Club TWiT today! https://twit.tv/clubtwit Club TWiT members can discuss this episode and leave feedback in the Club TWiT Discord.

All TWiT.tv Shows (MP3)
iOS Today 759: iPad Accessories

All TWiT.tv Shows (MP3)

Play Episode Listen Later Jul 3, 2025 45:08 Transcription Available


Mikah and Rosemary visit the world of iPad accessories that can truly transform your tablet experience, from the game-changing Magic Keyboard to creative stands and essential styli that unlock your iPad's full potential! Magic Keyboard & Physical Keyboards Apple Magic Keyboard - Premium keyboard case adds trackpad, extra USB-C charging port, and robust protection while transforming typing workflows Budget alternatives - Logitech Keys-to-Go and other Bluetooth keyboards offer function keys and media controls at lower price points Travel benefits - Bluetooth keyboards with media keys provide convenient remote control for video streaming and presentations Customization & Protection Vinyl wraps - Slickwraps and dbrand offer protective skins in textures like carbon fiber, marble, leather effects, and retro designs Practical benefits - Wraps add grip, protection, and personalization while helping identify devices in groups Apple Pencil Ecosystem Apple Pencil Pro - Latest model features squeeze gestures for tool palettes, barrel roll rotation, haptic feedback, hover detection, and Find My support Model comparison - Pro vs 2nd generation vs USB-C vs 1st generation, with varying features and price points Stand Solutions Satechi aluminum desktop stand - Heavy-duty stand with cable management, dual orientation support, and flexible positioning from flat to upright Satechi hub stand - Premium desktop solution combining stand with 4K HDMI out, USB-A & USB-C ports, SD readers, and audio jack Twelve South HoverBar Duo - Versatile system with clamp and desktop bases, Apple Pencil storage, and robust articulating arm Specialty Accessories Satechi Bluetooth remote - Compact media controller supporting PowerPoint, Keynote, streaming apps, and presentation software iPad cushion/pillow - UGREEN's washable lap cushion with multiple viewing angles, storage pockets, and ergonomic positioning Shortcuts Corner Van's question - How to discover full folder paths in Save File shortcuts after creation, since interface only shows last selected location Mr. Met's inspiration - Wanted shortcut to open Safari's new tab page instead of getting distracted by previous tabs App Cap Adobe Project Indigo - Beta computational photography app using multiple exposures for enhanced dynamic range and noise reduction PopSocket MagSafe Grips - Magnetic phone grips with easy attachment/removal and swappable tops Hosts: Mikah Sargent and Rosemary Orchard Contact iOS Today at iOSToday@twit.tv. Download or subscribe to iOS Today at https://twit.tv/shows/ios-today Want access to the ad-free video and exclusive features? Become a member of Club TWiT today! https://twit.tv/clubtwit Club TWiT members can discuss this episode and leave feedback in the Club TWiT Discord.

iOS Today (Video)
iOS 759: iPad Accessories - From basic tablet to pro workstation!

iOS Today (Video)

Play Episode Listen Later Jul 3, 2025 45:08


Mikah and Rosemary visit the world of iPad accessories that can truly transform your tablet experience, from the game-changing Magic Keyboard to creative stands and essential styli that unlock your iPad's full potential! Magic Keyboard & Physical Keyboards Apple Magic Keyboard - Premium keyboard case adds trackpad, extra USB-C charging port, and robust protection while transforming typing workflows Budget alternatives - Logitech Keys-to-Go and other Bluetooth keyboards offer function keys and media controls at lower price points Travel benefits - Bluetooth keyboards with media keys provide convenient remote control for video streaming and presentations Customization & Protection Vinyl wraps - Slickwraps and dbrand offer protective skins in textures like carbon fiber, marble, leather effects, and retro designs Practical benefits - Wraps add grip, protection, and personalization while helping identify devices in groups Apple Pencil Ecosystem Apple Pencil Pro - Latest model features squeeze gestures for tool palettes, barrel roll rotation, haptic feedback, hover detection, and Find My support Model comparison - Pro vs 2nd generation vs USB-C vs 1st generation, with varying features and price points Stand Solutions Satechi aluminum desktop stand - Heavy-duty stand with cable management, dual orientation support, and flexible positioning from flat to upright Satechi hub stand - Premium desktop solution combining stand with 4K HDMI out, USB-A & USB-C ports, SD readers, and audio jack Twelve South HoverBar Duo - Versatile system with clamp and desktop bases, Apple Pencil storage, and robust articulating arm Specialty Accessories Satechi Bluetooth remote - Compact media controller supporting PowerPoint, Keynote, streaming apps, and presentation software iPad cushion/pillow - UGREEN's washable lap cushion with multiple viewing angles, storage pockets, and ergonomic positioning Shortcuts Corner Van's question - How to discover full folder paths in Save File shortcuts after creation, since interface only shows last selected location Mr. Met's inspiration - Wanted shortcut to open Safari's new tab page instead of getting distracted by previous tabs App Cap Adobe Project Indigo - Beta computational photography app using multiple exposures for enhanced dynamic range and noise reduction PopSocket MagSafe Grips - Magnetic phone grips with easy attachment/removal and swappable tops Hosts: Mikah Sargent and Rosemary Orchard Contact iOS Today at iOSToday@twit.tv. Download or subscribe to iOS Today at https://twit.tv/shows/ios-today Want access to the ad-free video and exclusive features? Become a member of Club TWiT today! https://twit.tv/clubtwit Club TWiT members can discuss this episode and leave feedback in the Club TWiT Discord.

This Week in Health IT
Keynote: Partner Failures, Risk Stratification, and Strategic Translation With Alan Smith

This Week in Health IT

Play Episode Listen Later Jul 3, 2025 28:48 Transcription Available


July 3, 2025: Alan Smith, SVP and CIO of Lifepoint Health, joins Bill for a discussion on the top challenges facing CIOs. How do you balance immediate system stability when your organization is built through constant acquisitions? Al discusses his approach to the "CIO escape room" scenarios that define modern healthcare IT, from major partner outages to the ongoing tension between cloud-first strategies and financial realities. As healthcare organizations grapple with cost pressures while demanding more from their IT departments, Alan reveals how LifePoint navigates these competing forces and what it takes to build resilient systems in an industry where failure isn't an option. Key Points: 04:57 CIO Escape Room 14:14 The Importance of Inquisitiveness 17:31 Strategies in Virtual Leadership 26:12 Advice for Future Healthcare IT Leaders X: This Week Health LinkedIn: This Week Health Donate: Alex's Lemonade Stand: Foundation for Childhood Cancer

Stark Reflections on Writing and Publishing
EP 423 - Dear Writer: The World Needs Your Writing Now More Than Ever

Stark Reflections on Writing and Publishing

Play Episode Listen Later Jul 3, 2025 19:31


In this solo episode Mark expresses his frustration, anger, and anxiety over what's happening in the world right now, and reminds himself, and listeners, about the power of writing and why the world NEEDS you and your writing now more than ever before. Link to video of Mark's Keynote for The BookFest Spring 2025. "Writer, the World Needs You: Why Your Writing Is More Important Than Ever." https://www.youtube.com/watch?v=9c6usfgdtmg   Links of Interest: Manuscript Report (Mark's affiliate link) Buy Mark a Coffee Patreon for Stark Reflections Mark's YouTube channel Mark's Stark Reflections on Writing & Publishing Newsletter (Signup) An Author's Guide to Working With Bookstores and Libraries The Relaxed Author Buy eBook Direct Buy Audiobook Direct Publishing Pitfalls for Authors An Author's Guide to Working with Libraries & Bookstores Wide for the Win Mark's Canadian Werewolf Books This Time Around (Short Story) A Canadian Werewolf in New York Stowe Away (Novella) Fear and Longing in Los Angeles Fright Nights, Big City Lover's Moon Hex and the City Only Monsters in the Building The Canadian Mounted: A Trivia Guide to Planes, Trains and Automobiles Yippee Ki-Yay Motherf*cker: A Trivia Guide to Die Hard Merry Christmas! Shitter Was Full!: A Trivia Guide to National Lampoon's Christmas Vacation   The introductory, end, and bumper music for this podcast (“Laser Groove”) was composed and produced by Kevin MacLeod of www.incompetech.com and is Licensed under Creative Commons: By Attribution 3.0

Total Mikah (Audio)
iOS Today 759: iPad Accessories

Total Mikah (Audio)

Play Episode Listen Later Jul 3, 2025 45:08 Transcription Available


Mikah and Rosemary visit the world of iPad accessories that can truly transform your tablet experience, from the game-changing Magic Keyboard to creative stands and essential styli that unlock your iPad's full potential! Magic Keyboard & Physical Keyboards Apple Magic Keyboard - Premium keyboard case adds trackpad, extra USB-C charging port, and robust protection while transforming typing workflows Budget alternatives - Logitech Keys-to-Go and other Bluetooth keyboards offer function keys and media controls at lower price points Travel benefits - Bluetooth keyboards with media keys provide convenient remote control for video streaming and presentations Customization & Protection Vinyl wraps - Slickwraps and dbrand offer protective skins in textures like carbon fiber, marble, leather effects, and retro designs Practical benefits - Wraps add grip, protection, and personalization while helping identify devices in groups Apple Pencil Ecosystem Apple Pencil Pro - Latest model features squeeze gestures for tool palettes, barrel roll rotation, haptic feedback, hover detection, and Find My support Model comparison - Pro vs 2nd generation vs USB-C vs 1st generation, with varying features and price points Stand Solutions Satechi aluminum desktop stand - Heavy-duty stand with cable management, dual orientation support, and flexible positioning from flat to upright Satechi hub stand - Premium desktop solution combining stand with 4K HDMI out, USB-A & USB-C ports, SD readers, and audio jack Twelve South HoverBar Duo - Versatile system with clamp and desktop bases, Apple Pencil storage, and robust articulating arm Specialty Accessories Satechi Bluetooth remote - Compact media controller supporting PowerPoint, Keynote, streaming apps, and presentation software iPad cushion/pillow - UGREEN's washable lap cushion with multiple viewing angles, storage pockets, and ergonomic positioning Shortcuts Corner Van's question - How to discover full folder paths in Save File shortcuts after creation, since interface only shows last selected location Mr. Met's inspiration - Wanted shortcut to open Safari's new tab page instead of getting distracted by previous tabs App Cap Adobe Project Indigo - Beta computational photography app using multiple exposures for enhanced dynamic range and noise reduction PopSocket MagSafe Grips - Magnetic phone grips with easy attachment/removal and swappable tops Hosts: Mikah Sargent and Rosemary Orchard Contact iOS Today at iOSToday@twit.tv. Download or subscribe to iOS Today at https://twit.tv/shows/ios-today Want access to the ad-free video and exclusive features? Become a member of Club TWiT today! https://twit.tv/clubtwit Club TWiT members can discuss this episode and leave feedback in the Club TWiT Discord.

Heads Talk
257 - Paolo Sironi, Title: Fintech Series, IBM - The Fintech Globetrotter That Got Away… Until Now! - Part 1

Heads Talk

Play Episode Listen Later Jul 2, 2025 37:41


Honey, Hush
Reclaiming Your Power - Protecting Your Peace

Honey, Hush

Play Episode Listen Later Jul 1, 2025 13:10


We really are not in control of very much, but there are a few things we can do to protect our peace. Stop giving your best away to people and situations that leave you drained. This episode is all about reclaiming your power to set boundaries that allow you to thrive. www.EBCconsultingLLC.com

Life on Mars - A podcast from MarsBased
10 years without shortcuts or investors: the MarsBased keynote reveal

Life on Mars - A podcast from MarsBased

Play Episode Listen Later Jul 1, 2025 53:58 Transcription Available


After 10 years building MarsBased as a fully remote, bootstrapped, and values-driven tech company, we're finally sharing the full story. This keynote, recorded for our 10th anniversary, is a reflection on everything we've learned about building sustainable software, nurturing company culture, and growing a business without external investors, shortcuts or growth hacks.We talk about how we made remote work function from day one, why we chose to bootstrap instead of seeking venture capital, and how ethical decision-making has shaped every part of our journey. You'll also hear our philosophy on writing clean, maintainable code, and how long-term thinking has guided the way we run the company: slowly, intentionally, and with purpose.

Restaurant Unstoppable with Eric Cacciatore
1197: Samir Watter, COO of Layne's Chicken Fingers

Restaurant Unstoppable with Eric Cacciatore

Play Episode Listen Later Jun 30, 2025 79:25


Samir Watter is the COO at Layne's Chicken Fingers based in Dallas, TX. Samir joined Layne's in 2021 when there were only 7 total locations. Before that, he held impressive roles and big franchise companies like Denny's, where he worked for 10 years starting as AGM until heading the opening of 30 locations by the end of his tenure there. He also worked for La Salsa for 10 years as director of ops, where he opened 30 locations for that company as well. Today, Layne's has 25 locations and continues to grow. Join the Restaurant Unstoppable Network TODAY! Restaurant Unstoppable - EVOLVE! - Eric of Restaurant Unstoppable is now taking consultation and coaching calls! Book a consultation today! Schedule your call to become UNSTOPPABLE! Check out the website for more details: https://www.restaurantunstoppable.com/evolve Today's sponsors: Franchise Law Solutions - Thinking about franchising your restaurant? Success doesn't have to mean 100 units overnight. With the right plan, you can build a profitable, local or regional franchise brand. The team at Internicola Law Firm — franchise lawyers and franchise development experts — will show you how.  Visit www.franchiselawsolutions.com. US Foods: US Foods is hosting the event of the year, Food Fanatics 2025. August 19-20, 2025, at the Mandalay Bay, Las Vegas, NV. Network with over 5,000 Industry peers. Attend Zouk nightclub reception, expert breakout sessions, Keynote speeches, musical performances, and dramatic demonstrations, and sample the latest on-trend dishes. The Clock Is Ticking! Be Ready to Register on April 16 for Food Fanatics® 2025. To learn more, visit www.usfoods.com/foodfanatics2025 Restaurant Systems Pro - Join the 60-day Restaurant Systems Pro FREE TRAINING. This is something that has never been done before. This 60-day event is at no cost to you, but it is not for everyone. Fred Langley, CEO of Restaurant Systems Pro, will lead a group of restaurateurs through the Restaurant Systems Pro software and set up the systems for your restaurant. During the 60 days, Fred will walk you through the Restaurant Systems Pro Process and help you crush the following goals: Recipe Costing Cards; Guidance in your books for accounting; Cash controls; Sales Forecasting(With Accuracy); Checklists; Budgeting for the entire year; Scheduling for profit; More butts in seats and more… Click Here to learn more.  Let's make 2025 the year your restaurant thrives. Today's gues recommends:  Ovation Revel POS Guest contact info:  Website: https://www.layneschickenfingers.com Thanks for listening! Rate the podcast, subscribe, and share!  We are on Youtube: @RestaurantUnstoppable

Health Bite
232.The Courage to Begin Again: Finding Yourself Beyond Old Labels with Petra Kolber

Health Bite

Play Episode Listen Later Jun 30, 2025 43:21 Transcription Available


Leave Health Bite a Feedback.Click This Link.What if the key to living a life without regret isn't avoiding failure, but embracing the courage to try - especially when you're "too old" to start something new?In our achievement-obsessed culture, we're conditioned to believe that transformation should happen seamlessly, that successful people have linear paths, and that reinvention gets harder with age. But what if everything we've been told about change, identity, and "appropriate" timing is keeping us trapped in lives that no longer fit?In this deeply personal and universally inspiring episode of Health Bite, Dr. Adrienne Youdim sits down with keynote speaker, mindset coach, and author Petra Kolber to explore what it really takes to transform your life - not just once, but multiple times, and especially later in life.Who is Petra Kolber?Keynote speaker and mindset coach specializing in transformation and resilienceAuthor of "The Perfection Detox" - a guide to breaking free from perfectionist patternsFormer Reebok fitness athlete with over a decade representing the brand globallyAt age 61, boldly pivoted to become a DJ - proving reinvention has no expiration dateRecovering perfectionist who has navigated multiple major life transitionsWhat You'll Discover in This Episode:How perfectionism becomes a prison that keeps us from trying anything we might not excel at immediatelyWhy women especially struggle with owning their ambition and drive without apologizingHow our American obsession with work-based identity becomes a barrier to reinventionWhy This Episode Matters: Whether you're a high-achiever feeling stifled by your current success, someone navigating midlife transitions, or anyone who's ever thought "it's too late for me," this conversation offers permission to redefine what's possible at any age.This episode will help you:Distinguish between healthy ambition and perfectionist paralysis that prevents actionUnderstand why clinging too tightly to current identity blocks future growthLearn to create runway for exploration rather than burning bridges impulsivelyNavigate the spiritual and existential shifts that often accompany midlifeConnect with Petra Kolber:Website: PetraKolber.comLinkedin: https://www.linkedin.com/in/petrakolber/ Book: "The Perfection Detox" - https://www.amazon.com/Perfection-Detox-Critic-Bravely-Unleash/dp/0738234850 Ways that Dr. Adrienne Youdim Can Support You Join the Monthly Free Mind-Body Workshops: Participate in engaging mind-body practices designed to help manage your stress response. Register here. Sign Up for the Newsletter: Stay updated with valuable insights and resources by subscribing to the newsletter. Sign up here. Freebie alert. Register for our monthly free MindBody Workshop and receive a downloadable guide on emotional labeling to help you manage your emotions effectively. Connect with Dr. Adrienne Youdim Website :https://www.dradriennespeaks.com/ Instagram: https://www.instagram.com/dradrienneyoudim/

The Nurse Blake Podcast
The Two Moments That Changed My Life (LIVE at AWHONN)

The Nurse Blake Podcast

Play Episode Listen Later Jun 27, 2025 62:17


I wanted to share something really personal with you—my keynote presentation from the AWHONN Convention in Orlando, FL. In this talk, I open up about two moments that completely changed my life: being banned from donating blood in nursing school for being gay, and having my first panic attack after a long shift in the ICU.These moments could've broken me. But instead, they lit a fire. One pushed me to start Banned4Life and help lift the FDA's gay blood ban. The other led me to create my Nurse Blake social media accounts as a way to share my story & overcome burnout. Life gives us moments—some beautiful, some painful, some totally unexpected. My hope is that as you listen, you'll look at your own defining moments and realize: they don't have to hold you back. You have the power to take them, shape them, and turn them into something meaningful.___________I hope to see you later this Fall during my But Did You Die? Comedy Tour! Tickets on sale now at: nurseblake.com ___________I want to shoutout AWHONN for selecting me to be their Keynote and to everyone who attended my session!

ASCO Daily News
Immunotherapy at ASCO25: Drug Development, Melanoma Treatment, and More

ASCO Daily News

Play Episode Listen Later Jun 27, 2025 27:01


Dr. Diwakar Davar and Dr. Jason Luke discuss novel agents in melanoma and other promising new data in the field of immunotherapy that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Diwakar Davar: Hello. My name is Diwakar Davar, and I am welcoming you to the ASCO Daily News Podcast. I'm an associate professor of medicine and the clinical director of the Melanoma and Skin Cancer Program at the University of Pittsburgh's Hillman Cancer Center. Today, I'm joined by my colleague and good friend, Dr. Jason Luke. Dr. Luke is a professor of medicine. He is also the associate director of clinical research and the director of the Phase 1 IDDC Program at the University of Pittsburgh's Hillman Cancer Center. He and I are going to be discussing some key advancements in melanoma and skin cancers that were presented at the 2025 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode.  Jason, it is great to have you back on the podcast. Dr. Jason Luke: Thanks again so much for the opportunity, and I'm really looking forward to it. Dr. Diwakar Davar: Perfect. So we will go ahead and start talking a little bit about a couple of key abstracts in both the drug development immunotherapy space and the melanoma space. The first couple of abstracts, the first two, will cover melanoma. So, the first is LBA9500, which was essentially the primary results of RELATIVITY-098. RELATIVITY-098 was a phase 3 trial that compared nivolumab plus relatlimab in a fixed-dose combination against nivolumab alone for the adjuvant treatment of resected high-risk disease. Jason, do you want to maybe give us a brief context of what this is? Dr. Jason Luke: Yeah, it's great, thanks. So as almost all listeners, of course, will be aware, the use of anti–PD-1 immunotherapies really revolutionized melanoma oncology over the last 10 to 15 years. And it has become a standard of care in the adjuvant setting as well. But to review, in patients with stage III melanoma, treatment can be targeted towards BRAF with BRAF and MEK combination therapy, where that's relevant, or anti–PD-1 with nivolumab or pembrolizumab are a standard of care. And more recently, we've had the development of neoadjuvant approaches for palpable stage III disease. And in that space, if patients present, based on two different studies, either pembrolizumab or nivolumab plus ipilimumab can be given prior to surgery for somewhere in the 6- to 9-week range. And so all of these therapies have improved time-to-event endpoints, such as relapse-free or event-free survival. It's worth noting, however, that despite those advances, we've had a couple different trials now that have actually failed in this adjuvant setting, most high profile being the CheckMate-915 study, which looked at nivolumab plus ipilimumab and unfortunately was a negative study. So, with RELATIVITY-047, which was the trial of nivolumab plus relatlimab that showed an improvement in progression-free survival for metastatic disease, there's a lot of interest, and we've been awaiting these data for a long time for RELATIVITY-098, which, of course, is this adjuvant trial of LAG-3 blockade with relatlimab plus nivolumab. Dr. Diwakar Davar: Great. So with that, let's briefly discuss the trial design and the results. So this was a randomized, phase 3, blinded study, so double-blinded, so neither the investigators knew what the patients were getting, nor did the patients know what they were getting. The treatment investigational arm was nivolumab plus relatlimab in the fixed-dose combination. So that's the nivolumab standard fixed dose with relatlimab that was FDA approved in RELATIVITY-047. And the control arm was nivolumab by itself. The duration of treatment was 1 year. The patient population consisted of resected high-risk stage III or IV patients. The primary endpoint was investigator-assessed RFS. Stage and geography were the standard stratifying factors, and they were included, and most of the criteria were balanced across both arms. What we know at this point is that the 2-year RFS rate was 64% and 62% in the nivolumab and nivolumab-combination arms, respectively. The 2-year DMFS rate was similarly equivalent: 76% with nivolumab monotherapy, 73% with the combination. And similar to what you had talked about with CheckMate 915, unfortunately, the addition of LAG-3 did not appear to improve the RFS or DMFS compared to control in this patient population. So, tell us a little bit about your take on this and what do you think might be the reasons why this trial was negative? Dr. Jason Luke: It's really unfortunate that we have this negative phase 3 trial. There had been a lot of hope that the combination of nivolumab with relatlimab would be a better tolerated combination that increased the efficacy. So in the metastatic setting, we do have 047, the study that demonstrated nivolumab plus relatlimab, but now we have this negative trial in the adjuvant setting. And so as to why exactly, I think is a complicated scenario. You know, when we look at the hazard ratios for relapse-free survival, the primary endpoint, as well as the secondary endpoints for distant metastasis-free survival, we see that the hazard ratio is approximately 1. So there's basically no difference. And that really suggests that relatlimab in this setting had no impact whatsoever on therapeutic outcomes in terms of efficacy. Now, it's worth noting that there was a biomarker subanalysis that was presented in conjunction with these data that looked at some immunophenotyping, both from circulating T cells, CD8 T cells, as well as from the tumor microenvironment from patients who were treated, both in the previous metastatic trial, the RELATIVITY-047 study, and now in this adjuvant study in the RELATIVITY-098 study. And to briefly summarize those, what was identified was that T cells in advanced melanoma seemed to have higher expression levels of LAG-3 relative to T cells that are circulating in patients that are in the adjuvant setting. In addition to that, there was a suggestion that the magnitude of increase is greater in the advanced setting versus adjuvant. And the overall summary of this is that the suggested rationale for why this was a negative trial may have been that the target of LAG-3 is not expressed as highly in the adjuvant setting as it is in the metastatic setting. And so while the data that were presented, I think, support this kind of an idea, I am a little bit cautious that this is actually the reason for why the trial was negative, however. I would say we're not really sure yet as to why the trial was negative, but the fact that the hazard ratios for the major endpoints were essentially 1 suggests that there was no impact whatsoever from relatlimab. And this really makes one wonder whether or not building on anti–PD-1 in the adjuvant setting is feasible because anti–PD-1 works so well. You would think that even if the levels of LAG-3 expression were slightly different, you would have seen a trend in one direction or another by adding a second drug, relatlimab, in this scenario. So overall, I think it's an unfortunate circumstance that the trial is negative. Clearly there's going to be no role for relatlimab in the adjuvant setting. I think this really makes one wonder about the utility of LAG-3 blockade and how powerful it really can be. I think it's probably worth pointing out there's another adjuvant trial ongoing now of a different PD-1 and LAG-3 combination, and that's cemiplimab plus fianlimab, a LAG-3 antibody that's being dosed from another trial sponsor at a much higher dose, and perhaps that may make some level of difference. But certainly, these are unfortunate results that will not advance the field beyond where we were at already. Dr. Diwakar Davar: And to your point about third-generation checkpoint factors that were negative, I guess it's probably worth noting that a trial that you were involved with, KeyVibe-010, that evaluated the PD-1 TIGIT co-formulation of vibostolimab, MK-4280A, was also, unfortunately, similarly negative. So, to your point, it's not clear that all these third-generation receptors are necessarily going to have the same impact in the adjuvant setting, even if they, you know, for example, like TIGIT, and they sometimes may not even have an effect at all in the advanced cancer setting. So, we'll see what the HARMONY phase 3 trial, that's the Regeneron cemiplimab/fianlimab versus pembrolizumab control with cemiplimab with fianlimab at two different doses, we'll see how that reads out. But certainly, as you've said, LAG-3 does not, unfortunately, appear to have an impact in the adjuvant setting. So let's move on to LBA9501. This is the primary analysis of EORTC-2139-MG or the Columbus-AD trial. This was a randomized trial of encorafenib and binimetinib, which we will abbreviate as enco-bini going forward, compared to placebo in high-risk stage II setting in melanoma in patients with BRAF V600E or K mutant disease. So Jason, you know, you happen to know one or two things about the resected stage II setting, so maybe contextualize the stage II setting for us based on the trials that you've led, KEYNOTE-716, as well as CheckMate-76K, set us up to talk about Columbus-AD. Dr. Jason Luke: Thanks for that introduction, and certainly stage II disease has been something I've worked a lot on. The rationale for that has been that building off of the activity of anti–PD-1 in metastatic melanoma and then seeing the activity in stage III, like we just talked about, it was a curious circumstance that dating back about 7 to 8 years ago, there was no availability to use anti–PD-1 for high-risk stage II patients, even though the risk of recurrence and death from melanoma in the context of stage IIB and IIC melanoma is in fact similar or actually higher than in stage IIIA or IIIB, where anti–PD-1 was approved. And in that context, a couple of different trials that you alluded to, the Keynote-716 study that I led, as well as the CheckMate 76K trial, evaluated pembrolizumab and nivolumab, respectively, showing an improvement in relapse-free and distant metastasis-free survival, and both of those agents have subsequently been approved for use in the adjuvant setting by the US FDA as well as the European Medicines Agency.  So bringing then to this abstract, throughout melanoma oncology, we've seen that the impact of anti–PD-1 immunotherapy versus BRAF and MEK-targeted therapy have had very similar outcomes on a sort of comparison basis, both in frontline metastatic and then in adjuvant setting. So it was a totally reasonable question to ask: Could we use adjuvant BRAF and MEK inhibitor therapy? And I think all of us expected the answer would be yes. As we get into the discussion of the trial, I think the unfortunate circumstance was that the timing of this clinical trial being delayed somewhat, unfortunately, made it very difficult to accrue the trial, and so we're going to have to try to read through the tea leaves sort of, based on only a partially complete data set. Dr. Diwakar Davar: So, in terms of the results, they wanted to enroll 815 patients, they only enrolled 110. The RFS and DMFS were marginally improved in the treatment arm but certainly not significantly, which is not surprising because the trial had only accrued 16% to 18% of its complete accrual. As such, we really can't abstract from the stage III COMBI-AD data to stage II patients. And certainly in this setting, one would argue that the primary treatment options certainly remain either anti–PD-1 monotherapy, either with pembrolizumab or nivolumab, based on 716 or 76K, or potentially active surveillance for the patients who are not inclined to get treated.  Can you tell us a little bit about how you foresee drug development going forward in this space because, you know, for example, with HARMONY, certainly IIC disease is a part of HARMONY. We will know at least a little bit about that in this space. So what do you think about the stage IIB/C patient population? Is this a patient population in which future combinations are going to be helpful, and how would you think about where we can go forward from here? Dr. Jason Luke: It is an unfortunate circumstance that this trial could not be accrued at the pace that was necessary. I think all of us believe that the results would have been positive if they'd been able to accrue the trial. In the preliminary data set that they did disclose of that 110 patients, you know, it's clear there is a difference at a, you know, a landmark at a year. They showed a 16% difference, and that would be in line with what has been seen in stage III. And so, you know, I think it's really kind of too bad. There's really going to be no regulatory approach for this consideration. So using BRAF and MEK inhibition in stage II is not going to be part of standard practice moving into the future. To your point, though, about where will the field go? I think what we're already realizing is that in the adjuvant setting, we're really overtreating the total population. And so beyond merely staging by AJCC criteria, we need to move to biomarker selection to help inform which patients truly need the treatment. And in that regard, I don't think we've crystallized together as a field as yet, but the kinds of things that people are thinking about are the integration of molecular biomarkers like ctDNA. When it's positive, it can be very helpful, but in melanoma, we found that, unfortunately, the rates are quite low, you know, in the 10% to 15% range in the adjuvant setting. So then another consideration would be factors in the primary tumor, such as gene expression profiling or other considerations.  And so I think the future of adjuvant clinical trials will be an integration of both the standard AJCC staging system as well as some kind of overlaid molecular biomarker that helps to enrich for a higher-risk population of patients because on a high level, when you abstract out, it's just clearly the case that we're rather substantially overtreating the totality of the population, especially given that in all of our adjuvant studies to date for anti–PD-1, we have not yet shown that there's an overall survival advantage. And so some are even arguing perhaps we should even reserve treatment until patients progress. I think that's a complicated subject, and standard of care at this point is to offer adjuvant therapy, but certainly a lot more to do because many patients, you know, unfortunately, still do progress and move on to metastatic disease. Dr. Diwakar Davar: Let's transition to Abstract 2508. So we're moving on from the melanoma to the novel immunotherapy abstracts. And this is a very, very, very fascinating drug. It's IMA203. So Abstract 2508 is a phase 1 clinical update of IMA203. IMA203 is an autologous TCR-T construct targeting PRAME in patients with heavily pretreated PD-1-refractory metastatic melanoma. So Jason, in the PD-1 and CTLA-4-refractory settings, treatment options are either autologous TIL, response rate, you know, ballpark 29% to 31%, oncolytic viral therapy, RP1 with nivolumab, ORR about 30-ish percent. So new options are needed. Can you tell us a little bit about IMA203? Perhaps tell us for the audience, what is the difference between a TCR-T and traditional autologous TIL? And a little bit about this drug, IMA203, and how it distinguishes itself from the competing TIL products in the landscape. Dr. Jason Luke: I'm extremely enthusiastic about IMA203. I think that it really has transformative potential based on these results and hopefully from the phase 3 trial that's open to accrual now. So, what is IMA203? We said it's a TCR-T cell product. So what that means is that T cells are removed from a patient, and then they can be transduced through various technologies, but inserted into those T cells, we can then add a T-cell receptor that's very specific to a single antigen, and in this case, it's PRAME. So that then is contrasted quite a bit from the TIL process, which includes a surgical resection of a tumor where T cells are removed, but they're not specific necessarily to the cancer, and they're grown up in the lab and then given to the patient. They're both adoptive cell transfer products, but they're very different. One is genetically modified, and the other one is not. And so the process for generating a TCR-T cell is that patients are required to have a new biomarker that some may not be familiar with, which is HLA profiling. So the T-cell receptor requires matching to the concomitant HLA for which the peptide is bound in. And so the classic one that is used in most oncology practices is A*02:01 because approximately 48% of Caucasians have A*02:01, and the frequency of HLA in other ethnicities starts to become highly variable. But in patients who are identified to have A*02:01 genotype, we can then remove blood via leukapheresis or an apheresis product, and then insert via lentiviral transduction this T-cell receptor targeting PRAME. Patients are then brought back to the hospital where they can receive lymphodepleting chemotherapy and then receive the reinfusion of the TCR-T cells. Again, in contrast with the TIL process, however, these T cells are extremely potent, and we do not need to give high-dose interleukin-2, which is administered in the context of TIL. Given that process, we have this clinical trial in front of us now, and at ASCO, the update was from the phase 1 study, which was looking at IMA203 in an efficacy population of melanoma patients who were refractory at checkpoint blockade and actually multiple lines of therapy. So here, there were 33 patients and a response rate of approximately 50% was observed in this population of patients, notably with a duration of response approximately a year in that treatment group. And I realize that these were heavily pretreated patients who had a range of very high-risk features. And approximately half the population had uveal melanoma, which people may be aware is a generally speaking more difficult-to-treat subtype of melanoma that metastasizes to the liver, which again has been a site of resistance to cancer immunotherapy. So these results are extremely promising. To summarize them from what I said, it's easier to make TCR-T cells because we can remove blood from the patient to transduce the T cells, and we don't have to put them through surgery. We can then infuse them, and based on these results, it looks like the response rate to IMA203 is a little bit more than double what we expect from lifileucel. And then, whereas with lifileucel or TILs, we have to give high-dose IL-2, here we do not have to give high-dose IL-2. And so that's pretty promising. And a clinical trial is ongoing now called the SUPREME phase 3 clinical trial, which is hoping to validate these results in a randomized global study. Dr. Diwakar Davar: Now, one thing that I wanted to go over with you, because you know this trial particularly well, is what you think of the likelihood of success, and then we'll talk a little bit about the trial design. But in your mind, do you think that this is a trial that has got a reasonable likelihood of success, maybe even a high likelihood of success? And maybe let's contextualize that to say an alternative trial, such as, for example, the TebeAM trial, which is essentially a T-cell bispecific targeting GP100. It's being compared against SOC, investigator's choice control, also in a similarly heavily pretreated patient population. Dr. Jason Luke: So both trials, I think, have a strong chance of success. They are very different kinds of agents. And so the CD3 bispecific that you referred to, tebentafusp, likely has an effect of delaying progression, which in patients with advanced disease could have a value that might manifest as overall survival. With TCR-T cells, by contrast, we see a very high response rate with some of the patients going into very durable long-term benefit. And so I do think that the SUPREME clinical trial has a very high chance of success. It will be the first clinical trial in solid tumor oncology randomizing patients to receive a cell therapy as compared with a standard of care. And within that standard of care control arm, TILs are allowed as a treatment. And so it will also be the first study that will compare TCR-T cells against TILs in a randomized phase 3. But going back to the data that we've seen in the phase 1 trial, what we observe is that the duration of response is really connected to the quality of the response, meaning if you have more than a 50% tumor shrinkage, those patients do very, very well. But even in patients who have less than 50% tumor shrinkage, the median progression-free survival right now is about 4.5 months. And again, as we think about trial design, standard of care options for patients who are in this situation are unfortunately very bad. And the progression-free survival in that population is probably more like 2 months. So this is a trial that has a very high likelihood of being positive because the possibility of long-term response is there, but even for patients who don't get a durable response, they're likely going to benefit more than they would have based on standard chemotherapy or retreatment with an anti–PD-1 agent. Dr. Diwakar Davar: Really, a very important trial to enroll, a trial that is first in many ways. First of a new generation of TCR-T agents, first trial to look at cell therapy in the control arm, a new standard of efficacy, but potentially also if this trial is successful, it will also be a new standard of trial conduct, a new kind of trial, of a set of trials that will be done in the second-line immunotherapy-refractory space. So let's pivot to the last trial that we were going to discuss, which was Abstract 2501. Abstract 2501 is a first-in-human phase 1/2 trial evaluating BNT142, which is the first-in-class mRNA-encoded bispecific targeting Claudin-6 and CD3 in patients with Claudin-positive tumors. We'll talk a little bit about this, but maybe let's start by talking a little bit about Claudin-6. So Claudin-6 is a very interesting new target. It's a target that's highly expressed in GI and ovarian tumors. There are a whole plethora of Claudin-6-targeting agents, including T-cell bispecifics and Claudin-6-directed CAR-Ts that are being developed. But BNT142 is novel. It's a novel lipid nanoparticle LNP-encapsulated mRNA. The mRNA encodes an anti–Claudin-6 CD3 bispecific termed RiboMAB-021. And it then is administered to the patient. The BNT142-encoding mRNA LNPs are taken up by the liver and translated into the active drug. So Jason, tell us a little bit about this agent. Why you think it's novel, if you think it's novel, and let's talk a little bit then about the results. Dr. Jason Luke: So I certainly think this is a novel agent, and I think this is just the first of what will probably become a new paradigm in oncology drug development. And so you alluded to this, but just to rehash it quickly, the drug is encoded as genetic information that's placed in the lipid nanoparticle and then is infused into the patient. And after the lipid nanoparticles are taken up by the liver, which is the most common place that LNPs are usually taken up, that genetic material in the mRNA starts to be translated into the actual protein, and that protein is the drug. So this is in vivo generation, so the patient is making their own drug inside their body. I think it's a really, really interesting approach. So for any drug that could be encoded as a genetic sequence, and in this case, it's a bispecific, as you mentioned, CD3-Claudin-6 engager, this could have a tremendous impact on how we think about pharmacology and novel drug development moving into the future in oncology. So I think it's an extremely interesting drug, the like of which we'll probably see only more moving forward. Dr. Diwakar Davar: Let's maybe briefly talk about the results. You know, the patient population was heavily pretreated, 65 or so patients, mostly ovarian cancer. Two-thirds of the patients were ovarian cancer, the rest were germ cell and lung cancer patients. But let's talk a little bit about the efficacy. The disease control rate was about 58% in the phase 1 population as a whole, but 75% in the ovarian patient population. Now tell us a little bit about the interesting things about the drug in terms of the pharmacokinetics, and also then maybe we can pivot to the clinical activity by dose level. Dr. Jason Luke: Well, so they did present in their presentation at ASCO a proportionality showing that as higher doses were administered, that greater amounts of the drug were being made inside the patient. And so that's an interesting observation, and it's an important one, right? Suggesting that the pharmacology that we classically think of by administering drugs by IV, for example, would still be in play. And that did translate into some level of efficacy, particularly at the higher dose levels. Now, the caveat that I'll make a note of is that disease control rate is an endpoint that I think we have to be careful about because what that really means is sometimes a little bit unclear. Sometimes patients have slowly growing tumors and so on and so forth. And the clinical relevance of disease control, if it doesn't last at least 6 months, I think is probably pretty questionable. So I think these are extremely interesting data, and there's some preliminary sense that getting the dose up is going to matter because the treatment responses were mostly observed at the highest dose levels. There's also a caveat, however, that across the field of CD3 bispecific molecules like this, there's been quite a bit of heterogeneity in terms of the response rate, with some of them only really generating stable disease responses and other ones having more robust responses. And so I think this is a really interesting initial foray into this space. My best understanding is this molecule is not moving forward further after this, but I think that this really does set it up to be able to chase after multiple different drug targets on a CD3 bispecific backbone, both in ovarian cancer, but then basically across all of oncology. Dr. Diwakar Davar: Perfect. This is a very new sort of exciting arena where we're going to be looking at, in many ways, these programmable constructs, whether we're looking at in vivo-generated, in this case, a T-cell bispecific, but we've also got newer drugs where we are essentially giving drugs where people are generating in vivo CAR T, and also potentially even in vivo TCR-T. But certainly lots of new excitement around this entire class of drugs. And so, what we'd like to do at this point in time is switch to essentially the fact that we've got a very, very exciting set of data at ASCO 2025. You've heard from Dr. Luke regarding the advances in both early drug development but also in advanced cutaneous melanoma. And Jason, as always, thank you so much for sharing your very valuable and great, fantastic insights with us on the ASCO Daily News Podcast. Dr. Jason Luke: Well, thanks again for the opportunity. Dr. Diwakar Davar: And thank you to our listeners for taking your time to listen today. You will find the links to the abstracts that we discussed today in the transcript of this episode. And finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:    Dr. Diwakar Davar    @diwakardavar    Dr. Jason Luke @jasonlukemd Follow ASCO on social media:     @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn   Disclosures:     Dr. Diwakar Davar:      Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences     Consulting or Advisory Role: Instil Bio, Vedanta Biosciences     Consulting or Advisory Role (Immediate family member): Shionogi     Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, GSK, Merck, Arvus Biosciences, Arcus Biosciences     Research Funding (Inst.): Zucero Therapeutics     Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education Inventors: Diwakar Davar Filing Date: December 11, 2020 Country: United States MCC Reference: 10504-059PV1 Your Reference: 05545; and Application No.: 63/208,719 Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy     Dr. Jason Luke:     Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical, Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX     Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine     Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure     Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)     Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio

Restaurant Unstoppable with Eric Cacciatore
1196: Thom Crosby, CEO of Pal's Sudden Service

Restaurant Unstoppable with Eric Cacciatore

Play Episode Listen Later Jun 26, 2025 103:52


Thom Crosby is the CEO of Pal's Sudden Service, HQ'd in Kingstwon, TN. Pal's Sudden Service was first opened in 1956 in Kingstown, TN. Thom came on board in 1981 to help them grow. Thom's experience prior to Pal's was in corporate McDonald's and corporate Long John Silvers, as well as a franchisee with Wendy's. Today Thom is the CEO of Pal's and the company has 31 locations. All but 2 Pal's locations are drive-thru only.  Thom is a true believer and member of McClaskey Excellence Institute. David McClaskey was featured on the podcast, episode 1182, and you can learn more about him and his company here: https://www.restaurantunstoppable.com/mcclaskey-institute Join the Restaurant Unstoppable Network TODAY! Restaurant Unstoppable - EVOLVE! - Eric of Restaurant Unstoppable is now taking consultation and coaching calls! Book a consultation today! Schedule your call to become UNSTOPPABLE! Check out the website for more details: https://www.restaurantunstoppable.com/evolve Today's sponsors: Franchise Law Solutions - Thinking about franchising your restaurant? Success doesn't have to mean 100 units overnight. With the right plan, you can build a profitable, local or regional franchise brand. The team at Internicola Law Firm — franchise lawyers and franchise development experts — will show you how.  Visit www.franchiselawsolutions.com. US Foods: US Foods is hosting the event of the year, Food Fanatics 2025. August 19-20, 2025, at the Mandalay Bay, Las Vegas, NV. Network with over 5,000 Industry peers. Attend Zouk nightclub reception, expert breakout sessions, Keynote speeches, musical performances, and dramatic demonstrations, and sample the latest on-trend dishes. The Clock Is Ticking! Be Ready to Register on April 16 for Food Fanatics® 2025. To learn more, visit www.usfoods.com/foodfanatics2025 Restaurant Systems Pro - Join the 60-day Restaurant Systems Pro FREE TRAINING. This is something that has never been done before. This 60-day event is at no cost to you, but it is not for everyone. Fred Langley, CEO of Restaurant Systems Pro, will lead a group of restaurateurs through the Restaurant Systems Pro software and set up the systems for your restaurant. During the 60 days, Fred will walk you through the Restaurant Systems Pro Process and help you crush the following goals: Recipe Costing Cards; Guidance in your books for accounting; Cash controls; Sales Forecasting(With Accuracy); Checklists; Budgeting for the entire year; Scheduling for profit; More butts in seats and more… Click Here to learn more.  Let's make 2025 the year your restaurant thrives. Today's guest recommends: McClaskey Excellence Institute Guest contact info:  Website: https://www.palsweb.com/ Email: thom@palsweb.com Thanks for listening! Rate the podcast, subscribe, and share!  We are on Youtube: @RestaurantUnstoppable

This Week in Health IT
Keynote: From the Operating Room to the Boardroom with Michael Han

This Week in Health IT

Play Episode Listen Later Jun 26, 2025 29:05 Transcription Available


June 26, 2025: Michael Han, MD, Enterprise CMIO and VP of MultiCare Health System, discusses his transition from the operating room to the boardroom. He argues that the path forward isn't through automating clinical decisions, but through revolutionizing call centers, scheduling, prior authorizations, and referrals. Michael reveals how ambient clinical documentation must evolve beyond simple note-taking into a treasure trove of unstructured data that can drive actions across the entire care continuum—from pre-visit chart preparation to post-visit care coordination. The conversation explores how leaders establish credibility as they transition from the operating room to the boardroom. Key Points: 02:43 Impact of Ambient Clinical Documentation 05:51 AI and Large Language Models in Healthcare 10:27 The Role of CMIO in Digital Transformation 15:05 Leadership and Credibility in Healthcare 24:51 Speed Round: Personal Insights X: This Week Health LinkedIn: This Week Health Donate: Alex's Lemonade Stand: Foundation for Childhood Cancer

ASCO Daily News
Innovations in GU Cancer Treatment at ASCO25

ASCO Daily News

Play Episode Listen Later Jun 26, 2025 29:46


Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss important advances in the treatment of prostate, bladder, and kidney cancers that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I am Dr. Neeraj Agarwal, your guest host of the ASCO Daily News Podcast today. I am the director of the Genitourinary Oncology Program and a professor of medicine at the University of Utah Huntsman Cancer Institute and editor-in-chief of the ASCO Daily News.  I am delighted to be joined by Dr. Jeanny Aragon-Ching, a GU medical oncologist and the clinical program director of the GU Center at the Inova Schar Cancer Institute in Virginia. Today, we will be discussing some key abstracts in GU oncology that were presented at the 2025 ASCO Annual Meeting.  Our full disclosures are available in the transcript of this episode.  Jeanny, it is great to have you on the podcast. Dr. Jeanny Aragon-Ching: Oh, thank you so much, Neeraj. Dr. Neeraj Agarwal: Jeanny, let's begin with some prostate cancer abstracts. Let's begin with Abstract 5017 titled, “Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer.” Can you walk us through the design and the key findings of this first-in-human trial? Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So this study, presented by Dr. Capucine Baldini, introduces pasritamig, a first-in-class T-cell redirecting bispecific antibody that simultaneously binds KLK2 on prostate cancer cells and CD3 receptor complexes on T cells. KLK2 is also known as human kallikrein 2, which is selectively expressed in prostate tissue. And for reference, KLK3 is what we now know as the PSA, prostate-specific antigen, therefore making it an attractive and specific target for therapeutic engagement. Now, while this was an early, first-in-human, phase 1 study, it enrolled 174 heavily pretreated metastatic CRPC patients. So many were previously treated with ARPIs, taxanes, and radioligand therapy. So given the phase 1 nature of this study, the primary objective was to determine the safety and the RP2D, which is the recommended phase 2 dose. Secondary objectives included preliminary assessment of antitumor activity. So, pasritamig was generally well tolerated. There were no treatment-related deaths. Serious adverse events were rare. And in the RP2D safety cohort, where patients received the step-up dosing up to 300 mg of IV every 6 weeks, the most common treatment-related adverse events were low-grade infusion reactions. There was fatigue and grade 1 cytokine release syndrome, what we call CRS. And no cases of neurotoxicity, or what we call ICANS, the immune effector cell-associated neurotoxicity syndrome, reported. Importantly, the CRS occurred in just about 8.9% of patients. All were grade 1. No patients required tocilizumab or discontinued treatment due to adverse events. So, this suggests a favorable safety profile, allowing hopefully for outpatient administration without hospitalization, which will be very important when we're thinking about bispecifics moving forward. In terms of efficacy, pasritamig showed promising activity. About 42.4% of evaluable patients achieved a PSA50 response. Radiographic PFS was about 6.8 months. And among patients with measurable disease, the objective response rate was about 16.1% in those with lymph node or bone metastases, and about 3.7% in those with visceral disease, with a median duration of response of about 11.3 months. So, altogether, this data suggests that pasritamig may offer a well-tolerated and active new potential option for patients with metastatic CRPC.   Again, as a reminder, with the caveat that this is still an early phase 1 study. Dr. Neeraj Agarwal: Thank you, Jeanny. These are promising results for a bispecific T-cell engager, pasritamig, in prostate cancer. I agree, the safety and durability observed here stand out, and this opens the door for further development, possibly even in earlier disease settings.  So, shifting now from immunotherapy to the evolving role of genomics in prostate cancer. So let's discuss Abstract 5094, a real-world, retrospective analysis exploring the prognostic impact of homologous recombination repair gene mutations, especially BRCA1 and BRCA2 mutations, in metastatic hormone-sensitive prostate cancer. Can you tell us more about this abstract, Jeanny? Dr. Jeanny Aragon-Ching: Sure, Neeraj. So this study was presented by Dr. David Olmos, represents one of the largest real-world analyses we have evaluating the impact of homologous recombination repair, or what we would call HRR, alterations in metastatic hormone-sensitive prostate cancer. So, this cohort included 556 men who underwent paired germline and somatic testing. Now, about 30% of patients had HRR alterations, with about 12% harboring BRCA1 or BRCA2 mutations and 16% having alterations in other HRR genes. Importantly, patients were stratified via CHAARTED disease volume, and outcomes were examined across treatment approaches, including ADT alone, doublet therapy, and triplet therapy. The prevalence of BRCA and HRR alterations were about similar between the metastatic hormone-sensitive prostate cancer and the metastatic castrate-resistant prostate cancer, with no differences observed, actually, between the patients with high volume versus low volume disease.  So, the key finding was that BRCA and HRR alterations were associated with poor clinical outcomes in metastatic hormone-sensitive prostate cancer. And notably, the impact of these alterations may actually be even greater in metastatic hormone-sensitive prostate cancer than previously reported in metastatic CRPC. So, the data showed that when BRCA mutations are present, the impact of the volume of disease is actually limited. So, poor outcomes were observed across the board for both high-volume and low-volume groups. So, the analysis showed that patients with HRR alterations had significantly worse outcomes compared to patients without HRR alterations. Median radiographic progression-free survival was about 20.5 months for the HRR-altered patients versus 30.6 months for the non-HRR patients, with a hazard ratio of 1.6. Median overall survival was 39 months for HRR-altered patients compared to 55.7 months for the non-HRR patients, with a hazard ratio of 1.5. Similar significant differences were observed when BRCA-mutant patients were compared with patients harboring non-BRCA HRR mutations. Overall, poor outcomes were independent of treatment of ARPI or taxanes. Dr. Neeraj Agarwal: Thank you, Jeanny. So, these data reinforce homologous recombination repair mutations as both a predictive and prognostic biomarker, not only in the mCRPC, but also in the metastatic hormone-sensitive setting as well. It also makes a strong case for incorporating genomic testing early in the disease course and not waiting until our patients have castration-resistant disease. Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. And I think this really brings home the point and the lead up to the AMPLITUDE trial, which is LBA5006, a phase 3 trial that builds on this very concept of testing with a PARP inhibitor, niraparib, in the hormone-sensitive space. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the AMPLITUDE trial, a phase 3 trial presented by Dr. Gerhardt Attard, enrolled 696 patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations. 56% of these patients had BRCA1 and BRCA2 mutations. Patients were randomized to receive abiraterone with or without niraparib, a PARP inhibitor. The majority of patients, 78% of these patients, had high-volume metastatic hormone-sensitive prostate cancer, and 87% of these patients had de novo metastatic HSPC. And 16% of these patients received prior docetaxel, which was allowed in the clinical trial. So, with a median follow-up of nearly 31 months, radiographic progression-free survival was significantly prolonged with the niraparib plus abiraterone combination, and median was not reached in this arm, compared to abiraterone alone, which was 29.5 months, with a hazard ratio of 0.63, translating to a 37% reduction in risk of progression or death. This benefit was even more pronounced in the BRCA1 and BRCA2 subgroup, with a 48% reduction in risk of progression, with a hazard ratio of 0.52. Time to symptomatic progression also improved significantly across all patients, including patients with BRCA1, BRCA2, and HRR mutations. Although overall survival data remain immature, early trends favored the niraparib plus abiraterone combination. The safety profile was consistent with prior PARP inhibitor studies, with grade 3 or higher anemia and hypertension were more common but manageable. Treatment discontinuation due to adverse events remained low at 11%, suggesting that timely dose modifications when our patients experience grade 3 side effects may allow our patients to continue treatment without discontinuation. These findings support niraparib plus abiraterone as a potential new standard of care in our patients with metastatic hormone-sensitive prostate cancer with HRR alterations, and especially in those who had BRCA1 and BRCA2 mutations. Dr. Jeanny Aragon-Ching: Thank you, Neeraj. This trial is especially exciting because it brings PARP inhibitors earlier into the treatment paradigm. Dr. Neeraj Agarwal: Exactly. And it is exciting to see the effect of PARP inhibitors in the earlier setting.  So Jeanny, now let's switch gears a bit to bladder cancer, which also saw several impactful studies. Could you tell us about Abstract 4502, an exploratory analysis from the EV-302 trial, which led to approval of enfortumab vedotin plus pembrolizumab for our patients with newly diagnosed metastatic bladder cancer? So here, the authors looked at the outcomes in patients who achieved a confirmed complete response with EV plus pembrolizumab. Dr. Jeanny Aragon-Ching: Sure, Neeraj. So, EV-302 demonstrated significant improvements in progression-free and overall survival for patients previously treated locally advanced or metastatic urothelial cancer, I'll just call it metastatic UC, as a frontline strategy, establishing EV, which is enfortumab vedotin, plus pembro, with pembrolizumab as standard of care in this setting.  So, this year at ASCO, Dr Shilpa Gupta presented this exploratory responder analysis from the phase 3 EV-302 trial. Among 886 randomized patients, about 30.4% of patients, this is about 133, in the EV+P arm, and 14.5% of the patients in the chemotherapy arm, achieved a confirmed complete response. They call it the CCR rates. So for patients who achieved this, median PFS was not reached with EV+P compared to 26.9 months with chemotherapy, with a hazard ratio of 0.36, translating to a 64% reduction in the risk of progression. Overall survival was also improved. So the median OS was not reached in either arm, but the hazard ratio favored the EV+P at 0.37, translating to a 63% reduction in the risk of death. The median duration of complete response was not reached with EV+P compared to 15.2 months with chemotherapy. And among those patients who had confirmed CRs at 24 months, 78% of patients with the EV+P arm remained progression-free, and around 95% of the patients were alive, compared to 54% of patients who were progression-free and 86% alive of the patients in the chemotherapy arm. Safety among responders were also consistent with prior reports. Grade 3 or higher treatment-related adverse events occurred in 62% of EV+P responders and 72% of chemotherapy responders. Most adverse events were managed with dose modifications, and importantly, no treatment-related deaths were reported among those who were able to achieve complete response.  So these findings further reinforce EV and pembro as the preferred first-line therapy for metastatic urothelial carcinoma, offering a higher likelihood of deep, durable responses with a fairly manageable safety profile. Dr. Neeraj Agarwal: Thank you for the great summary, Jeanny. These findings underscore the depth and durability of responses achievable with this combination and also suggest that achieving a response may be a surrogate for long-term benefit in patients with metastatic urothelial carcinoma.  So now, let's move to Abstract 4503, an exploratory ctDNA analysis from the NIAGARA trial, which evaluated perioperative durvalumab, an immune checkpoint inhibitor, in muscle-invasive bladder cancer. So what can you tell us about this abstract? Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. So, in NIAGARA, presented by Dr. Tom Powles, the addition of perioperative durvalumab to neoadjuvant chemotherapy, gem/cis, significantly improved event-free survival, overall survival, and pathologic complete response in patients with cisplatin-eligible muscle-invasive bladder cancer. Recall that this led to the U.S. FDA approval of this treatment regimen on March 28, 2025.  So, a planned exploratory analysis evaluated the ctDNA dynamics and their association with clinical outcomes, which was the one presented recently at ASCO. So, the study found that the incidence of finding ctDNA positivity in these patients was about 57%. Following neoadjuvant treatment, this dropped to about 22%, with ctDNA clearance being more common in the durvalumab arm, about 41%, compared to the chemotherapy control arm of 31%. Notably, 97% of patients who remained ctDNA positive prior to surgery failed to achieve a pathologic CR. So, this indicates a strong association between ctDNA persistence and lack of tumor eradication. So, postoperatively, only about 9% of patients were ctDNA positive. So, importantly, durvalumab conferred an event-free survival benefit regardless of ctDNA status at both baseline and post-surgery. Among patients who were ctDNA positive at baseline, durvalumab led to a hazard ratio of 0.73 for EFS. So, this translates to a 27% reduction in the risk of disease recurrence, progression, or death compared to the control arm. In the post-surgical ctDNA-positive group, the disease-free survival was also improved with a hazard ratio of 0.49, translating to a 51% reduction in the risk of recurrence.  So, these findings underscore the prognostic value of ctDNA and suggest that durvalumab provides clinical benefit irrespective of molecular residual disease status. So, the data also supports that ctDNA is a promising biomarker for future personalized strategies in the perioperative treatment of muscle-invasive bladder cancer. Dr. Neeraj Agarwal: Thank you, Jeanny. It is great to see that durvalumab is improving outcomes in these patients regardless of ctDNA status. However, based on these data, presence of ctDNA in our patients warrants a closer follow-up with imaging studies, because these patients with positive ctDNA seem to have a higher risk of recurrence. Dr. Jeanny Aragon-Ching: I agree, Neeraj.  Let's round out the bladder cancer discussion with Abstract 4518, which reported the interim results of SURE-02, which is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab in cisplatin-ineligible muscle-invasive bladder cancer. Can you tell us more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure, Jeanny. So, Dr Andrea Necchi presented interim results from the SURE-02 trial. This is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by a response-adapted bladder-sparing treatment and adjuvant pembrolizumab in patients with muscle-invasive bladder cancer.  So, in this interim analysis, 40 patients were treated and 31 patients were evaluable for efficacy. So, the clinical complete response rate was 38.7%. All patients achieving clinical complete response underwent bladder-sparing approach with a repeat TURBT instead of radical cystectomy. Additionally, 51.6% of patients achieved excellent pathologic response with a T stage of 1 or less after neoadjuvant therapy. The treatment was well tolerated, with only 12.9% of patients experiencing grade 3 or higher adverse events without needing dose reduction of sacituzumab. Molecular profiling, interestingly, showed that clinical complete response correlated with luminal and genomically unstable subtypes, while high stromal gene expression was associated with lack of response.  These results suggest that sacituzumab plus pembrolizumab combination has promising activity in this setting, and tolerability, and along with other factors may potentially allow a bladder preservation approach in a substantial number of patients down the line. Dr. Jeanny Aragon-Ching: Yeah, agree with you, Neeraj. And the findings are very provocative and support completing the full trial enrollment and further exploration of this strategy in muscle-invasive bladder cancer in order to improve and provide further bladder-sparing strategies. Dr. Neeraj Agarwal: Agree. So, let's now turn to the kidney cancer, starting with Abstract 4505, the final overall analysis from CheckMate-214 trial, which evaluated nivolumab plus ipilimumab, so dual checkpoint inhibition strategy, versus sunitinib in our patients with metastatic clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So, the final 9-year analysis of the phase 3 CheckMate-214 trial confirms the long-term superiority of nivolumab and ipilimumab over sunitinib for first-line treatment of advanced metastatic renal cell carcinoma. So, this has a median follow-up of 9 years. Overall survival remains significantly improved with the combination. So, in the ITT patient population, the intention-to-treat, the hazard ratio for overall survival was 0.71. So, this translates to a 29% reduction in the risk of death. 31% of patients were alive at this 108-month follow-up compared to 20% only in those who got sunitinib. So, similar benefits were observed in the intermediate- and poor-risk groups with a hazard ratio of 0.69, and 30% versus 19% survival at 108 months.  Importantly, a delayed benefit was also seen in those favorable-risk patients. So, the hazard ratio for overall survival improved from 1.45 in the initial report and now at 0.8 at 9 years follow-up, with 35% of patients alive at 108 months compared to 22% in those who got sunitinib. Progression-free survival also favored the nivo-ipi arm across all risk groups. At 96 months, the probability of remaining progression-free was about 23% compared to 9% in the sunitinib arm in the ITT patient population, 25% versus 9% in the intermediate- and poor-risk patients, and 13% compared to 11% in the favorable-risk patients. Importantly, at 96 months, 48% of patients in the nivo-ipi responders remained in response compared to just 19% in those who got sunitinib. And in the favorable-risk group, 36% of patients who responded remained in response, although data were not available for sunitinib in this subgroup.  So, this data reinforces the use of nivolumab and ipilimumab as a durable and effective first-line effective strategy for standard of care across all risk groups for advanced renal cell carcinoma. Dr. Neeraj Agarwal: Thank you, Jeanny. And of course, since ipi-nivo data were presented, several other novel ICI-TKI combinations have emerged. And I'm really hoping to see very similar data with TKI-ICI combinations down the line. It is really important to note that we are not seeing any new safety signals with the ICI combinations or ICI-based therapies, which is very reassuring given the extended exposure. Dr. Jeanny Aragon-Ching: Absolutely agree with you there, Neeraj.  Now, going on and moving on to Abstract 4514, which is the KEYNOTE-564 trial, and they reported on the 5-year outcomes of adjuvant pembrolizumab in clear cell RCC in patients who are at high risk for recurrence. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the KEYNOTE-564 trial established pembrolizumab monotherapy as the first adjuvant regimen to significantly improve both disease-free survival and overall survival compared to placebo after surgery for patients with clear cell renal cell carcinoma. So, Dr Naomi Haas presented the 5-year update from this landmark trial.  A total of 994 patients were randomized to receive either pembrolizumab or placebo. The median follow-up at the time of this analysis was approximately 70 months. Disease-free survival remained significantly improved with pembrolizumab. The median DFS was not reached with pembrolizumab compared to 68.3 months with placebo, with a hazard ratio of 0.71, translating to a 29% reduction in risk of recurrence. At 5 years, 60.9% of patients receiving pembrolizumab remained disease-free compared to 52.2% with placebo. Overall survival also favored pembrolizumab. The hazard ratio for OS was 0.66, translating to a 34% reduction in risk of death, with an estimated 5-year overall survival rate of 87.7% with pembrolizumab compared to 82.3% for placebo. Importantly, these benefits were consistent across all key subgroups, including patients with sarcomatoid features. In addition, no new serious treatment-related adverse events have been reported in the 3 years since treatment completion.  So, these long-term data confirm pembrolizumab as a durable and effective standard adjuvant therapy for patients with resected, high-risk clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Thank you for that wonderful summary, Neeraj. Dr. Neeraj Agarwal: That wraps up our kidney cancer highlights. Any closing thoughts, Jeanny, before we conclude? Dr. Jeanny Aragon-Ching: It's been so wonderful reviewing these abstracts with you, Neeraj. So, the 2025 ASCO Annual Meeting showcased a lot of transformative data across GU cancers, from first-in-class bispecifics to long-term survival in RCC. And these findings are already shaping our clinical practices. Dr. Neeraj Agarwal: I agree. And we have covered a broad spectrum of innovations in GU cancers with strong clinical relevance.  So, thank you, Jeanny, for joining me today and sharing your insights.  And thank you to our listeners for joining us. You will find links to the abstracts discussed today in the transcript of this episode. If you find these conversations valuable, please take a moment to rate, review, and subscribe to the ASCO Daily News Podcast wherever you listen. Thank you so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:    Dr. Neeraj Agarwal     @neerajaiims     Dr. Jeanny Aragon-Ching   Follow ASCO on social media:       @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn       Disclosures:   Dr. Neeraj Agarwal:   Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences  Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas  Dr. Jeanny Aragon-Ching:   Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc., Pfizer/EMD Serono   Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis,    Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb, Astellas/Seattle Genetics

The Bitcoin Standard Podcast
279. Bitcoin and Tether: Las Vegas Keynote

The Bitcoin Standard Podcast

Play Episode Listen Later Jun 24, 2025 44:35


Saifedean's keynote talk at the Bitcoin Conference, discussing whether Tether can save the dollar. Also included is an interview with Natalie Brunell at the conference.Enjoyed this episode? Join Saifedean's online learning platform to take part in weekly podcast seminars, access Saifedean's four online economics courses, and read his writing, including his new book, Principles of Economics! Find out more on Saifedean.com!The Saif House - High quality cloth hardcover bitcoin books by Saifedean & more delivered worldwide, with 10% off for paying in bitcoin - TheSaifHouse.com

She Who Dares
296. Why Your Wedding Business Stuck at $100K (2025 Summit Keynote)

She Who Dares

Play Episode Listen Later Jun 24, 2025 37:48 Transcription Available


You didn't start your business to stay stuck. If you're ready to finally hit 6 or 7 figures WITHOUT burning out — book a call with our team → https://weddingproceo.com/applicationEver feel like no matter how hard you hustle, you just can't break past that $100K mark? Working every weekend, buried in client work, and still stuck? Wedding Pro, it's not your clients—it's how you're spending your time.In this keynote from the 2025 Wedding Pro CEO Summit, I'm breaking down exactly why you're stuck and how to start thinking (and acting) like the CEO of a 6- or 7-figure wedding business. Let's get you out of the weeds and calculate what your hour is really worth.✨ Need help delegating or calculating your CEO hourly rate? Check out Dan Martell's book “Buy Back Your Time” — it's required reading around here.The (FREE!)ASSUME Sales Training: 2x your wedding bookings in 30 days—step by step. Thousands of wedding pros have already used it to land more clients immediately! http://weddingproceo.com/freetrainingorg========================= EPISODE BLOG, LINKS & MORE:https://weddingproceo.com/why-your-wedding-business-stuck-at-100k/========================= Thank you for tuning in to this episode of the Wedding Pro CEO Podcast. If you find these strategies helpful, make sure to share this episode with your fellow wedding pros. And remember, in the world of weddings, it's all about building genuine relationships and showcasing your best work. Until next time, keep shining, CEOs!Heads up, friend! Some of the links I share may be affiliate links, which means I may earn a small commission if you decide to purchase—at no extra cost to you. I only recommend tools and resources I actually use and love, and that I believe will help you grow a profitable, sustainable business you're obsessed with.PLEASE SUPPORT THE PODCAST! LEAVE A REVIEW HERE: https://ratethispodcast.com/swdHave a question you'd like Brandee to answer? Ask here: http://bit.ly/3ZoqPmz=========================FREE TRAINING for Wedding Business OwnersTake the Wedding Pro CEO's free GAP assessmentSupport the showFREE TRAINING for Wedding Business Owners Take the Wedding Pro CEO's free GAP assessmentSupport the show

The GaryVee Audio Experience
How You Can Save Money, Build a Business, and Stay Happy | GaryVee NAC Success Resources Keynote 2019

The GaryVee Audio Experience

Play Episode Listen Later Jun 13, 2025 33:44


I gave this keynote at the NAC Success Resources event in 2019 — and I went deep on the real shit that holds people back. It's not lack of resources. It's not bad luck. It's entitlement, insecurity, and the need to impress others instead of doing what actually makes you happy.If you've ever felt like you're stuck or not moving fast enough, this episode is a wake-up call. I break down the 5 core pieces of value that I believe will unlock your path to success — and most of them have nothing to do with business tactics and everything to do with mindset.Whether you're just starting or scaling, this talk will push you to get brutally honest with yourself and start executing.